Ghodse's Drugs and Addictive Behaviour

A Guide to Treatment

Ghodse's Drugs and Addictive Behaviour

This classic text provides a comprehensive, accessible overview of substance misuse and dependence with an emphasis on practical and evidence-based approaches to the assessment, management and prevention of a wide range of drug-related problems, in a variety of clinical and social settings. The book includes definitions of terms, and describes the effects and clinical characteristics of all substances of misuse. The theoretical background to these topics is clearly explained. For the fourth edition, every chapter has been revised to include the most up-to-date information, with the latest international data on the extent of the world drug problem. There is detailed emphasis on harm minimization, AIDS and hepatitis C and entirely new coverage of tobacco addiction and its management. This is an essential guide for all healthcare workers, health policy specialists, counselors and those seeking to train in areas related to addiction and substance misuse.


 Reviews:

'… when it comes to applying the evidence of the real-life clinical situations that face a psychiatrist working with people who use illegal drugs, this book reaches the parts that a systematic review-driven approach cannot always reach …' British Journal of Psychiatry

'… every psychiatrist should have access to a copy for reference.' Journal of Psychosomatic Research

'… well researched, thorough and logically ordered.' Drug and Alcohol Review

'Not only does it provide a comprehensive overview of the subject but it is also written in a clear, lucid style that communicates easily with broad readership. Professor Ghodse's text will remain a comprehensive guide and essential reading for a new generation of professionals working in the field of addictions.' Psychological Medicine

'Highly readable, and including illuminating sections on historical and cultural aspects of substance use … a comprehensive tool that will be invaluable to occupational physicians, particularly the Hamid Ghodse substance abuse assessment questionnaire in Appendix 4.' Occupational Medicine

Gillick v. West Norfolk & Wisbech AHA & DHSS [1985] 3 WLR, HL.
Abou-Saleh MT & Foley S (2008). Prevalence and incidence of hepatitis C in drug users: a review. Addictive Disorders & Their Treatment, 7, 190–8.
Abou-Saleh MT & Miller J (1999). The management of drug misuse in primary care. Primary Care Psychiatry, 5, 49–56.
Abou-Saleh MT (2004). Dual diagnosis: management within a psychosocial context. Advances in Psychiatric Treatment, 10, 352–60.
Abou-Saleh MT , Davis P , Rice P , et al. (2008). The effectiveness of behavioural interventions in the primary prevention of Hepatitis C amongst injecting drug users: a randomised controlled trial and lessons learned. Harm Reduction Journal, 5, 25.
Advisory Committee on Drug Dependence (1968). Cannabis. The Wootton Report. London: HMSO.
Advisory Council on the Misuse of Drugs (1982). Treatment and Rehabilitation. London: HMSO.
Advisory Council on the Misuse of Drugs (1993). AIDS and Drug Misuse Update. London: HMSO.
Advisory Council on the Misuse of Drugs (2000). Reducing Drug-Related Deaths. London: Advisory Council on the Misuse of Drugs.
Advisory Council on the Misuse of Drugs (2003). Hidden Harm – Responding to the Needs of the Children of Problem Drug Users. London: ACMD. http://drugs.homeoffice.gov.uk/publication-search/acmd/hidden-harm.
Alcohol Concern (1999). Proposals for a National Alcohol Strategy for England. London: Alcohol Concern.
Alem A & Shibbe T (1997). Khat induced psychosis and its medico-legal implication: a case report. Ethiopian Medical Journal, 35, 137–41.
Alem A , Kebede D & Kullgren G (1999). The prevalence and socio-demographic correlates of khat chewing in Butajira, Ethiopia. Acta Psychiatrica Scandinavica. Supplementum, 100, 84–91.
Allwright S , Bradley F , Long J et al. (2000). Prevalence of antibodies to hepatitis B, hepatitis C and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. British Medical Journal, 321, 78–82.
American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn (DSM-III-R). Washington, DC: APA.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). Washington, DC: APA.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). Washington, DC: APA.
American Psychiatric Association (1996). Practice guideline for the treatment of patients with nicotine dependence. The American Journal of Psychiatry, 153 (10 Suppl), S1–S31.
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text rev (DSM-IV-TR). Washington, DC: APA.
American Psychiatric Association (2005). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Arlington, VA: American Psychiatric Press Inc.
Anderson DJ , McGovern JP & DuPont RL (1999). The origins of the Minnesota Model of addiction treatment: a first person account. Journal of Addictive Diseases, 18, 107–14.
Anderson P (1995). Alcohol and the risk of physical harm. In Alcohol and Public Policy: Evidence and Issues, ed. HD Holder & G Edwards . Oxford: Oxford University Press.
Anderson S & Berridge V (2000). Opium in twentieth-century Britain: pharmacists, regulation and people. Addiction, 95, 23–36.
Andrados J-LR (1995). The influence of family, school and peers on adolescent drug misuse. The International Journal of the Addictions, 30, 1407–23.
Andreasson G (2008). Drugs in Sweden: Methods of Prevention. A Review of the Evidence. Östersund: Swedish National Institute of Public Health. Available at: www.fhi.se.
Anglin D , Spears KL & Hutson HR (1997). Flunitrazepam and its involvement in date or acquaintance rape. Academy of Emergency Medicine, 4, 323–6.
Anthenelli RM (1994). The initial evaluation of the dual diagnosis patient. Psychiatric Annals, 24, 427–31.
Anton RF , O'Malley SS , Ciraulo DA , et al. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA, 295, 2003–17.
Arber E (ed.) (1895). The Essayes of a Prentise in the Divine Art of Poesie and A Counterblaste to Tobacco. English Reprint Series. London: Constable.
Arif A & Westermeyer J (eds.) (1990). Methadone Maintenance in the Management of Opioid Dependence: an International Review. New York: Praeger.
Armstrong A , Hine J , Hacking S , et al. (2005). Children, Risk and Crime: the On Track Youth Lifestyles Surveys. Home Office Research Study 278. January 2005. London: Home Office Research Development and Statistics Directorate. www.homeoffice.gov.uk/rds/pdfs05/hors278.pdf.
Ashton CH (2001). Pharmacology and effects of cannabis: a brief review. British Journal of Psychiatry, 178, 101–6.
Ashton H (1991). Protracted withdrawal syndromes from benzodiazepines. Journal of Substance Abuse Treatment, 8, 19–28.
Association of Forensic Physicians, and Royal College of Psychiatrists (2006). Substance Misuse Detainees in Police Custody: Guidelines for Clinical Management, 3rd edn. Report of a Medical Working Group. Council report CR132. May 2006. London: Royal College of Psychiatrists. www.rcpsych.ac.uk/files/pdfversion/cr132.pdf.
Association of Forensic Physicians, and Royal College of Psychiatrists (2006). Substance Misuse Detainees in Police Custody: Guidelines for Clinical Management, 3rd edn. Report of a Medical Working Group. Council report CR132. May 2006. London: Royal College of Psychiatrists. www.rcpsych.ac.uk/files/pdfversion/cr132.pdf.
Austin GA (1978). Perspective on the History of Psychoactive Substance Use. Rockville, MD: National Institute of Drug Abuse.
Aveyard P & West R (2007). Managing smoking cessation. British Medical Journal, 335, 37–41.
Bahrke MS , Yesalis CE & Brower KJ (1998). Anabolic-androgenic steroid abuse and performance-enhancing drugs among adolescents. Child & Adolescent Psychiatric Clinics of North America, 7, 821–38.
Ball D , Pembrey M & Stephens D (2007). Genomics. In Drugs and the Future; Brain Science, Addiction and Society, ed. D Nutt , TW Robbins , GV Stimson , M Ince & A Jackson . London: Elsevier.
Ball JC & Ross A (1991). The Effectiveness of Methadone Maintenance Treatment: Patients, Programmes, Services and Outcome. New York: Springer-Verlag.
Banal R , McRobbie D & Hicks A (2003). Identification of medication-related attendances at an A & E department. Journal of Clinical Pharmacy and Therapeutics, 28, 41–5.
Bayer I & Ghodse H (1999). Evolution of international drug control 1945–1995. Bulletin on Narcotics, LI (1 and 2), 1–17.
Bayer I & Ghodse H (1999). Evolution of international drug control 1945–1995. Bulletin on Narcotics, LI (1 and 2), 1–17.
Beck AT , Wright FD , Newman CF & Liese BS (2001). Cognitive Therapy of Substance Abuse. London: Guilford Press.
Bell CS & Battjes R (eds.) (1985). Prevention Research: Deterring Drug Abuse among Children and Adolescents. NIDA research monograph 63. Rockville, MD: Department of Health and Human Services.
Bennett T (1998). Drugs and Crime: The Results of Research on Drug Testing and Interviewing Arrestees. Home Office Research Study 183. London: Home Office Research and Statistics Directorate. www.homeoffice.gov.uk/rds/pdfs/hors183.pdf.
Bennett T (2000). Drugs and Crime: The Results of the Second Developmental Stage of the NEW-ADAM Programme. Home Office Research Study 205. London: Home Office Research and Statistics Directorate. www.homeoffice.gov.uk/rds/pdfs/hors205.pdf.
Berridge V & Edwards G (1987). Opium and the People: Opiate Use in Nineteenth Century England. New Haven, CT: Yale University Press.
Berridge V (1979). Morality and medical science: concepts of narcotic addiction in Britain, 1820–1926. Annals of Science, 36, 67.
Bewley TH , Ben-Arie O & James IP (1968). Morbidity and mortality from heroin dependence. 1. Survey of heroin addicts known to the Home Office. British Medical Journal, 1, 725–6.
Bmj Publishing Group (1999). HIV in pregnancy and early childhood. Drug and Therapeutics Bulletin, 37, 65–7.
Bmj Publishing Group (1999). HIV in pregnancy and early childhood. Drug and Therapeutics Bulletin, 37, 65–7.
Booth A , Brennan A , Meier PS , et al. (2008). The Independent Review of the Effects of Alcohol Pricing and Promotion. Summary of Evidence to Accompany Report on Phase 1. Sheffield: the School of Health and Related Research, University of Sheffield. Available at: www. dh.gov.uk/en/Publichealth/Healthimprovement/Alcoholmisuse.
Boys A , Marsden J , Fountain J , et al. (1999). What influences young people's use of drugs? A qualitative study of decision making. Drugs: Education, Prevention and Policy, 6, 373–87.
Boys A , Marsden J , Fountain J , et al. (1999). What influences young people's use of drugs? A qualitative study of decision making. Drugs: Education, Prevention and Policy, 6, 373–87.
Brecher M , Wang B-W , Wong H & Morgan JP (1988). Phencyclidine and violence: Clinical and legal issues. Journal of Clinical Psychopharmacology, 8, 397–401.
Breslau N , Peterson EL , Schultz LR , Chilcoat HD & Andreski P (1998). Major depression and stages of smoking. A longitudinal investigation. Archives of General Psychiatry, 55, 161–6.
Brewster JM (1986). Prevalence of alcohol and other drug problems among physicians. JAMA, 255, 1913–20.
British National Formulary (2008) British National Formulary, 56. London: RPS Publishing. Available at: www.bnf.org.
Brook JS , Balka EB & Whiteman M (1999). The risks for late adolescence of early adolescence marijuana use. American Journal of Public Health, 89, 1549–54.
Broome KM , Flynn PM & Simpson DD (1999). Psychiatric comorbidity measures as predictors of retention in drug abuse treatment programs. Health Services Research, 334, 791–806.
Broome KM , Simpson DD & Joe GW (1999). Patient and program attributes related to treatment process indicators in DATOS. Drug and Alcohol Dependence, 57, 127–35. Available at: www.datos.org/publicationsyear.html#1999Publications.
Brown GS , Lambert MJ , Jones ER & Minami T (2005). Identifying highly effective psychotherapists in a managed care environment. American Journal of Managed Care, 11, 513–20.
Brown S , Inskip H & Barraclough B (2000). Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212–17.
Bucknell P & Ghodse AH (1996). Misuse of Drugs, 3rd edn. London: Sweet and Maxwell.
Bucknell P & Ghodse AH (1996). Misuse of Drugs, 3rd edn. London: Sweet and Maxwell.
Bucknell P & Ghodse H (1996). Misuse of Drugs, 3rd edn. London: Sweet and Maxwell.
Cabinet Office (1998). Tackling Drugs to Build a Better Britain: The Government's Ten-Year Strategy for Tackling Drugs Misuse. London: The Stationery Office.
Cabinet Office (2000). The United Kingdom Anti-Drug Co-ordinator's Second National Plan. London: Cabinet Office.
Cami J , Bigelow GE , Griffiths RR & Drummond DC (eds.) (1991). Clinical testing of drug abuse liability. (Special issue.) British Journal of Addiction, 86, 1525–652.
Caplehorn JRM , Stella M , Dalton YN , et al. (1994). Retention in methadone maintenance and heroin addicts' risk of death. Addiction, 89, 203–7.
Carrol KM , Fenton LR , Ball SA , et al. (2004). Efficacy of disulfiram and cognitive behavior therapy in cocaine dependent outpatients: a randomized placebo-controlled trial. Archives of General Psychiatry, 61, 264–72.
Carter BL & Tiffany ST (1999). Meta analysis of cue reactivity in addiction research. Addiction, 94, 327–40.
Carvalho V , Pinsky I , De Souza e Silva R , et al. (1995). Drug and alcohol use and family characteristics: a study among Brazilian high school students. Addiction, 90, 65–72.
Center on Addiction, and Substance Abuse at Columbia University (CASA) (1995). Legalisation: Panacea or Pandora's Box. White Paper 1. New York: CASA.
Charney DA , Paraherakis AM & Gill KJ (2000). The treatment of sedative-hypnotic dependence: evaluating clinical predictors of outcome. Journal of Clinical Psychiatry, 61, 190–5.
Chaudry HR , Moss HB , Bashir A & Suliman T (1991). Cannabis psychosis following bhang ingestion. British Journal of Addiction, 86, 1075–81.
Cheng W & Henry J (2005). Ethical, legal and practical aspects of testing. In Addiction at Work. Tackling Drug Use and Misuse in the Workplace, ed. H Ghodse . London: Gower, pp. 185–208.
Chick JD (1999). Management of alcohol dependence. Proceedings of the Royal College of Physicians of Edinburgh, 29, 43–50.
Childers SR (1991). Minireview: opioid receptor-coupled second messenger systems. Life Science, 48, 1991–2003.
Chopra G & Smith J (1974). Psychotic reactions following cannabis use in East Indians. Archives of General Psychiatry, 30, 24–7.
Christofides J & Egerton M (2005). Drug screening and detection. In Addiction at Work. Tackling Drug Use and Misuse in the Workplace, ed. H Ghodse . London: Gower, pp. 151–70.
Churchill AC , Burgess P , Pead J & Gill T (1993). Measurement of the severity of amphetamine dependence. Addiction, 88, 1335–40.
Compton DR , Harris LS , Lichtman AH & Martin BR (1996). Marihuana. In Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach, ed. CR Schuster & MJ Kuhar . Berlin: Springer-Verlag, pp. 83–158.
Connell PH (1958). Amphetamine Psychosis. Maudsley monograph 5. London: Oxford University Press.
Connors CJ , Di Clemente CC , Dermen MKH , et al. (2000). Predicting the therapeutic alliance in alcoholism treatment. Journal of Studies on Alcohol, 61, 139–49.
Cook CH (1988). The Minnesota model in the management of drug and alcohol dependency: miracle, method or myth? British Journal of Addiction, 83, 625–34.
Cook RF , Bernstein AD , Aarrington TL , Andrew CM & Marshall GA (1995). Methods of assessing drug use prevalence in the workplace: a comparison of self-report, urinalysis and hair analysis. International Journal of the Addictions, 30, 403–26.
Corkery JM (1997). Statistics of Drug Addicts Notified to the Home Office, United Kingdom 1996. Home Office Statistical Bulletin 22/97. London: Home Office Research and Statistics Department. www.homeoffice.gov.uk/rds/pdfs/hosb2297.pdf.
Corkery JM (2004). The relationship between notifications to the Home Office Addicts Index and deaths of notified addicts. The Drug and Alcohol Professional, 2, 31–8.
Corkery JM (2004). The relationship between notifications to the Home Office Addicts Index and deaths of notified addicts. The Drug and Alcohol Professional, 2, 31–8.
Corkery JM , Schifano F , Ghodse AH & Oyefeso A (2004). The effects of methadone and its role in fatalities. Human Psychopharmacology: Clinical and Experimental, 19, 565–76.
Cornish JW & O'Brien CP (1998). Developing medications to treat cocaine dependence: a new direction. Current Opinion in Psychiatry, 11, 249–51.
Corrigall WA , Franklin KBJ , Coen KM & Clarke PBS (1992). The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology, 107, 285–9.
Cottrell D , Childs-Clarke A & Ghodse AH (1985). British opiate addicts: an 11-year follow-up. British Journal of Psychiatry, 146, 448–50.
Crawford MJ , Patton R , Touquet R , et al. (2004). Screening and referral for brief intervention of alcohol misusing patients in an Accident and Emergency Department: a pragmatic randomised controlled trial. The Lancet, 364, 1334–9.
Crawford V (1996). Comorbidity of substance misuse and psychiatric disorders. Current Opinion in Psychiatry, 9, 231–4.
Crawford V (1997). Injecting drug use. Current Opinion in Psychiatry, 10, 215–19.
Crofts N , Jolley D , Kaldor J , van Beek I & Wodak A (1997). Epidemiology of hepatitis C virus infection among injecting drug users in Australia. Journal of Epidemiology and Community Health, 51, 692–7.
Crome I , Ghodse H , Gilvarry E & McArdle P (eds.) (2004). Young People and Substance Misuse. London: Gaskell.
Crome I , Ghodse H , Gilvarry E & McArdle P (eds.) (2004). Young People and Substance Misuse. London: Gaskell.
Crome IB & McArdle P (2008). Prevention programmes. In Young People and Substance Misuse, ed. I Crome , H Ghodse , E Gilvarry & P McArdle . London: Gaskell, pp. 15–30.
Curran V & Drummond C (2007). Psychological treatments of substance misuse and dependence. In Drugs and the Future: Brain Science, Addiction and Society, ed. D Nutt , TW Robbins , GV Stimson , M Ince & A Jackson . Oxford: Academic Press, pp. 209–40.
Dåderman AM & Lidberg L (1999). Flunitrazepam (Rohypnol) abuse in combination with alcohol causes premeditated grievous violence in male juvenile offenders. Journal of American Academy of Psychiatry and Law, 27, 83–9.
Das Gupta S (1990). Identifying the problem. In Substance Abuse and Dependence, ed. AH Ghodse & D Maxwell . London: Macmillan Press, pp. 53–79.
Day E (ed.) (2007) Clinical Topics in Addiction. London: Royal College of Psychiatrists.
Day E , Ison J , Keaney F , Butwal N & Strang J (2005). A National Survey of Inpatient Drug Services in England. Research Briefing 12. London: National Treatment Agency for Substance Misuse.
De Leon G (2000). The Therapeutic Community. Theory, Model and Method. New York: Springer Publishing.
Degenhardt L , Hall W & Lynskey M (2001). Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction, 96, 1603–14.
Denney R (1997). None for the Road: Understanding Drink-Driving. London: Shaw and Sons.
Department of Health (1995). Sensible Drinking. The Report of an Inter-Departmental Working Group. London: Department of Health.
Department of Health (2001). Hepatitis C: Guidance for Those Working with Drug Users. Gateway Reference 2001. London: Department of Health. www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publications PolicyAndGuidance/DH_4008723.
Department of Health (2001). Hepatitis C: Guidance for Those Working with Drug Users. Gateway Reference 2001. London: Department of Health. www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publications PolicyAndGuidance/DH_4008723.
Department of Health (2001). Hepatitis C: Guidance for Those Working with Drug Users. Gateway Reference 2001. London: Department of Health. www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publications PolicyAndGuidance/DH_4008723.
Department of Health (2002). Mental Health Policy Implementation Guide: Dual Diagnosis Good Practice Guide. London: Department of Health.
Department of Health (2008). HIV Post-exposure Prophylaxis: Guidance from the UK Chief Medical Officers' Expert Advisory Group on AIDS. Gateway Reference 10380. London: Department of Health. www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_088185.
Department of Health (2008). Safe, Sensible, Social – Consultation on Further Action. London: Department of Health.
Department of Health (2008). Statistical Bulletin: Statistics from the Regional Drug Misuse Databases on Drug Misusers in Treatment in England, 2000/01. Bulletin 2001/33. 31 December 2001. London: Department of Health. www.dh.gov.uk/en/Publicationsandstatistics/Statistics/StatisticalWorkAreas/Statisticalpublichealth/DH_4080051?IdcService=GET_FILE&dID=24950& Rendition=Web.
Department of Health (2008). The Cost of Alcohol Harm to the NHS in England. London: Department of Health.
Department of Health (England), and the devolved administrations (2007). Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive.
Department of Health (England), and the devolved administrations (2007). Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive.
Department of Health (England), and the devolved administrations (2007). Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive. www.nta.nhs.uk/publications/documents/clinical_guidelines_2007.pdf.
Department of Health (England), and the devolved administrations (2007). Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive. www.nta.nhs.uk/publications/documents/clinical_guidelines_2007.pdf.
Department of Health (England), and the devolved administrations (2007). Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive. www.nta.nhs.uk/publications/documents/clinical_guidelines_2007.pdf.
Department of Health (England), the Scottish Government, Welsh Assembly Government, and Northern Ireland Executive (2007). Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health. www.nta.nhs.uk/publications/documents/clinical_guidelines_2007.pdf.
Department of Health Statistical Division 1E (date accessed: 12 June 2009). Prescription Cost Analysis System. Available at: www.dh.gov.uk/en/Publicationsandstatistics/Statistics/StatisticalWorkAreas/Statisticalhealthcare/DH_4086488.
Department of Health, and Human Services (1988). The Health Consequences of Smoking: a Report of the Surgeon General. Rockville, MD: DOHHS.
Department of Health, and Human Services (2007). Results from the 2006 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies. Available at: www.samsha.gov.
Department of Health, Scottish Office Department of Health, Welsh Office, Department of Health and Social Services, Northern Ireland (1991). Drug Misuse and Dependence: Guidelines on Clinical Management. London: HMSO.
Department of Health, Scottish Office Department of Health, Welsh Office, Department of Health and Social Services, Northern Ireland (1999). Drug Misuse and Dependence: Guidelines on Clinical Management. London: HMSO.
Department of Health, Scottish Office Department of Health, Welsh Office, Department of Health and Social Services, Northern Ireland (1999). Drug Misuse and Dependence: Guidelines on Clinical Management. London: The Stationery Office.
Department of Health, Social Services, and Public Safety (2006). New Strategic Direction for Alcohol and Drugs 2006–2011. 8 May 2006. Belfast: Department of Health, Social Services and Public Safety. http://www.dhsspsni.gov.uk/nsdad-finalversion-may06.pdf.
Department of Health, Social Services, and Public Safety for Northern Ireland (2008). Statistics from the Northern Ireland Drug Addicts Index 2007. Statistical Bulletin PHIRB 1/2008. March 2008. Belfast: Department of Health, Social Services and Public Safety. www.dhsspsni.gov.uk/addicts-index-report-2007.pdf.
Department of Health, The Scottish Office Home, and Health Department, and Welsh Office (1994). Substance Misuse Detainees in Police Custody. Guidelines for Clinical Management. Report of a Medical Working Group. London: HMSO.
Departmental Committee on Morphine, and Heroin Addiction (1926). Report of the Departmental Committee on Morphine and Heroin Addiction. (Rolleston Committee.) London: HMSO.
Des Jarlais DC , Hagan H , Friedman SR , et al. (1995). Maintaining low seroprevalence in populations of injecting drug users. Journal of the American Medical Association, 274, 1226–31.
Di Chiara G , Bassareo V , Fenu S , et al. (2004). Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology, 47 (Suppl 1), 227–41.
DiClemente CC , Prochaska JO , Fairhurst SK , et al. (1991). The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. Journal of Consulting and Clinical Psychology, 59, 295–304.
Dixon WE (1927). The physiological effects of smoking. Practitioner, 118, 20–8.
Dole VP & Nyswander MA (1965). Medical treatment for diacetylmorphine (heroin) addiction. JAMA, 193, 645–56.
Donmall MC (1999). UK Monitoring of problem drug users: the Drug Misuse Database – a system based on Regional Centres. European Addiction Research, 5, 185–90.
Donmall MC , Hickman M & Glavas R (2000). The New National Drug Treatment Monitoring System Part 1: Requirements & Part 2 Technical Specification. A review consultancy for the Department of Health London, University of Manchester and Imperial College London.
Dorn N (1981). Social analyses of drugs in health education and the media. In Drug Problems in Britain: A Review of Ten Years, ed. G Edwards & C Busch . London: Academic Press, pp. 281–304.
Driver and Vehicle Licensing Agency (2008). For Medical Practitioners. At a Glance Guide to the Current Medical Standards of Fitness to Drive. Swansea: DVLA. Available at: www.dvla.gov.uk.
Drummond C , Ghodse H & Chengappa S (2007). Use of investigations in the diagnosis and management of alcohol use disorders. In Clinical Topics in Addiction, ed. E Day . London: Royal College of Psychiatrists, pp. 113–29.
Drummond C , Oyefeso A , Phillips T , et al. (2005). Alcohol Needs Assessment Research Project (ANARP): The 2004 National Alcohol Needs Assessment for England. London: Department of Health.
Drummond DC (1997). Alcohol interventions: do the best things come in small packages? Addiction, 92, 375–9.
Drummond DC (2000). UK Government announces first major relaxation in the alcohol licensing laws for nearly a century. Addiction, 95, 997–8.
Drummond DC (2009). Services for alcohol use disorders. In New Oxford Textbook of Psychiatry, 2nd edn, ed. M Gelder , N Andreasen , J Lopez-Ibor & J Geddes . Oxford: Oxford University Press.
Dyer KR & White JM (1997). Patterns of symptom complaints in methadone maintenance patients. Addiction, 92 (11), 1445–55.
Dyer KR (2005). Methadone maintenance treatment and mood disturbances: pharmacological and psychological implications. Heroin Addiction and Related Clinical Problems, 7, 5–10.
Dyer KR , Foster DJR , White JM , et al. (1999). Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patient: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clinical Pharmacology and Therapeutics, 65, 685–94.
Dyer KR , White JM , Foster DJR , et al. (2001). The relationship between mood state and plasma methadone concentration in maintenance patients. Journal of Clinical Psychopharmacology, 21, 78–84.
Eddy NB , Halbach H , Isbell H & Seevers MH (1965). Drug dependence: its significance and characteristics. Bulletin of the World Health Organization, 32, 723.
Editor CDR (1999). AIDS and HIV infection in the United Kingdom: monthly report.Communicable Disease Report, 9, 277–80.
Edwards G & Busch C (eds.) (1981). Drug Problems in Britain: A Review of Ten Years. London: Academic Press.
Edwards G & Gross MM (1976). Alcohol dependence: provisional description of a clinical syndrome. British Medical Journal, 1, 1058–61.
Edwards G , Anderson P , Babor TF , et al. (1994). Alcohol Policy and the Public Good. Oxford: Oxford University Press.
Edwards G , Marshall EJ & Cook CCH (1997). Working towards normal drinking. In The Treatment of Drinking Problems, 3rd edn. Cambridge: Cambridge University Press.
Edwards G , Marshall EJ & Cook CCH (2003). The Treatment of Drinking Problems, 4th edn. Cambridge: Cambridge University Press.
Eley S , Gallop K , McIvor G , Morgan K & Yates R (2002). Drug Treatment and Testing Orders: Evaluation of the Scottish Pilots. Edinburgh: Scottish Executive Social Research. Available at: www.scotland.gov.uk/Publications/2002/10/15537/11671.
Emrick C (1989). Alcoholics Anonymous: membership characteristics and effectiveness as treatment. In Recent Developments in Alcoholism: Treatment and Research, ed. M Galanter . New York: Plenum Press, pp. 37–53.
Engstrom A , Adamsson C , Allebeck P & Rydberg U (1991). Mortality in patients with substance abuse: a follow-up in Stockholm County, 1973–84. International Journal of Addiction, 89, 851–7.
European Monitoring Centre for Drugs and Drug Addiction (1999). Annual Report on the State of the Drugs Problem in the European Union. Luxembourg: Office for the Official Publications of the European Communities. www.emcdda.europa.eu/attachements.cfm/att_37341_EN_AR99EN.pdf.
European Monitoring Centre for Drugs and Drug Addiction (2008). Annual Report 2008: the State of the Drugs Problem in Europe. November 2008. Luxembourg: Office for the Official Publications of the European Communities. www.emcdda.europa.eu/attachements.cfm/att_64227_EN_EMCDDA_AR08_En.pdf.
Evans EB (1998). Pharmacology of inhalants. In Handbook of Substance Abuse. Neurobehavioral Pharmacology, ed. RE Tarter , RT Ammerman & PJ Ott . New York: Plenum, pp. 255–62.
Falkowski J & Ghodse AH (1989). Undergraduate medical school training in psychoactive drugs and rational prescribing in the United Kingdom. British Journal of Addictions, 84, 1539–42.
Falkowski J , Ghodse AH , Dickinson R & Khan I (1989). An international survey of the educational activities of schools of pharmacy on psychoactive drugs. Bulletin of the World Health Organization, 67, 561–4.
Fals-Stewart W , Kashdan TB , O'Farrell TJ , et al. (2002). Behavioral couples therapy for drug abusing patients: effects on partner violence. Journal of Substance Abuse Treatment, 22, 87–96.
Farmer R & Ghodse AH (1993). Therapies for substance misuse. In Recent Advances in Clinical Psychiatry, ed. K Granvill-Grossman . Edinburgh: Churchill Livingstone.
Farrell M & Marsden J (2005). Drug-Related Mortality among Newly Released Offenders 1998 to 2000. Home Office Online Report 40/05. 27 October 2005. London: Home Office Research Development and Statistics Directorate. www.homeoffice.gov.uk/rds/pdfs05/rdsolr 4005.pdf.
Farrell M & Marsden J (2008). Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction, 103, 251–5.
Farrell M , Howes S , Bebbington P , et al. (2001). Nicotine, alcohol and drug dependence and psychiatric comorbidity. British Journal of Psychiatry, 179, 432–7.
Favrat B , Zimmermann G , Zullino D , et al. (2006). Opioid antagonist detoxification under anaesthesia versus traditional clonidine detoxification combined with an additional week of psychosocial support: a randomized clinical trial. Drug and Alcohol Dependence, 81, 109–16.
Field-Smith ME , Butland BK , Ramsey JD & Anderson HR (2009) Trends in Death Associated with Abuse of Volatile Substances, 1971–2007. Report 22. 31 July 2009. London: St George's University of London. Available at: www.vsareport.or.
Fiellin DA , Moore BA , Sullivan LE , et al. (2008) Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. American Journal on Addictions, 17, 116–20.
Finnegan LP & Kaltenbach K (1992). Neonatal abstinence syndrome. In Primary Pediatric Care, 2nd edn, ed. RA Hoekelman & NM Nelson . St Louis: Mosby Year Book.
Fischman VS (1968). Stimulant users in the Californian Rehabilitation Center. International Journal of the Addictions, 3, 113–30.
Flood-Page C , Campbell S , Harrington V & Miller J (2000). Youth Crime: Findings from the 1998/99 Youth Lifestyles Survey. Home Office Research Study 209. London: Home Office Research Development and Statistics Directorate. www.homeoffice.gov.uk/rds/pdfs/hors209.pdf.
Flynn PM , Kristiansen PL , Porto JV & Hubbard RL (1999). Costs and benefits of treatment for cocaine addiction in DATOS. Drug and Alcohol Dependence, 57, 167–74.
Foley S & Abou-Saleh MT (2009). Risk behaviours and transmission of hepatitis C in injecting drug users. Addictive Disorders & Their Treatment, 8, 13–21.
Foulds J & Ghodse H (1995). The role of nicotine in tobacco smoking: implications for tobacco control policy. Journal of the Royal Society for the Promotion of Health, 115, 225–30.
Foulds J & Ghodse H (1995). Treating tobacco dependence. Advances in Psychiatric Treatment, 1, 116–23.
Foulds J , Stapleton J , Feyerabend C , et al. (1992). Effect of transdermal nicotine patches on cigarette smoking: a double blind crossover study. Psychopharmacology, 106, 421–7.
Fox BS (1997). Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug and Alcohol Dependence, 48, 153–8.
Fox C , Cook C , Loughlin P & Mangal R (2008). Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews (Online), 1, CD004332. DOI: 10.1002/14651858.CD004332.
Frankau IM & Stanwell PM (1960). The treatment of drug-addiction. The Lancet, 2, 1377–9.
Fried MW , Shiffman ML , Reddy KR , et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine, 347, 975–82.
Frontera JA & Gradon JD (2000). Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. Clinical Infectious Diseases, 30, 374–9.
Fuller E (ed.) (2008). Drug Use, Smoking and Drinking Among Young People in England 2007. 17 July 2008. London: NHS – The Health and Social Care Information Centre. www.ic.nhs.uk/webfiles/publications/sdd07/SDD%20Main%20report%2007%20%2808%29-Standard.pdf.
Gallager DW & Primus RJ (1993). Benzodiazepine tolerance and dependence: GABA A receptor complex locus of change. In Neurochemistry of Drug Dependence, ed. S Wonnacott & G Glunt . London: Portland, pp. 135–51.
Garbutt JC , West SL , Carey TS , Lohr KN & Crews FT (1999). Pharmacological treatment of alcohol dependence. A review of the evidence. JAMA, 281, 1318–25.
Gatrad R , Gatrad A & Sheikh A (2007). Hookah smoking. British Medical Journal, 335, 20.
Gawin FH & Ellingwood EH (1990). Consequences and correlates of cocaine abuse: clinical phenomenology. In Cocaine and the Brain, ed. ND Volkow & AC Swan . New Brunswick, NJ: Rutgers University Press, pp. 155–78.
Gawin FH , Khalsa ME & Ellingwood E (1994). Stimulants. In Textbook of Substance Abuse Treatment, ed. M Galanter & HD Kleber . Washington, DC: American Psychiatric Press, pp. 111–39.
General Medical Council (1995). Good Medical Practice. London: General Medical Council. www.gmc.uk.org.
General Medical Council (1997). Serious Communicable Diseases. London: GMC Publications.
General Medical Council (2006). Good Medical Practice; paragraph 37. London: GMC. Available at: www.gmc-uk.org/guidance/good_medical_practice/relationships_with_patients/confidentiality.asp.
Gerra G , Zaimovic A , Giusti F , et al. (2001). Lofexidine versus clonidine in rapid opiate detoxification. Journal of Substance Abuse Treatment, 21, 11–17.
Gerra G , Zaimovic A , Rustichelli P , et al. (2000). Rapid opiate detoxification in outpatient treatment: relationship with naltrexone compliance. Journal of Substance Abuse Treatment, 18, 185–91.
Gerstein DR , Johnson RA , Harwood HJ , et al. (1994). Evaluating Recovery Services: The California Drug and Alcohol Treatment Assessment (CALDATA). Sacramento, CA: Department of Alcohol and Drug Programs.
Getahun A & Krikorian AD (1983). The economic and social importance of khat and suggested research and services. In Proceedings of the International Conference on Khat, January 17–21, Antannarivo, Madagascar.
Getter H , Litt MD , Kadden RM & Cooney NL (1992). Measuring treatment process in coping skills and interactional group therapies for alcoholism. International Journal of Group Psychotherapy, 42, 419–30.
Ghodse AH & Creighton FJ (1984). Opioid analgesics and narcotic antagonists. In Meyler's Side Effects of Drugs, 11th edn, ed. MNG Dukes . Amsterdam: Elsevier, pp. 137–155.
Ghodse AH & Kreek M-J (1997). A rave of ecstasy. Current Opinion in Psychiatry, 10, 191–3.
Ghodse AH & Maxwell D (eds.) (1990). Substance Abuse and Dependence: An Introduction for the Caring Professions. London: Macmillan Press.
Ghodse AH (1977). Casualty departments and the monitoring of drug dependence. British Medical Journal, 1, 1381–2.
Ghodse AH (1986). Cannabis psychosis. British Journal of Addiction, 81, 473–8.
Ghodse AH (1989). Benefit risk of agonist-antagonist analgesics. British Journal of Addiction, 84, 455–7.
Ghodse AH (1990). Problems of maternal substance abuse. In Substance Abuse and Dependence, ed. AH Ghodse & D Maxwell . London: Macmillan Press, pp. 16–231.
Ghodse AH (1994). Combined use of drugs and alcohol. Current Opinion in Psychiatry, 7, 249–51.
Ghodse AH (1995). Substance misuse and personality disorders. Current Opinion in Psychiatry, 8, 177–9.
Ghodse AH , Bewley TH , Kearney MK & Smith SE (1986). Mydriatic response to topical naloxone in opiate abusers. British Journal of Psychiatry, 148, 44–6.
Ghodse AH , Creighton FJ & Bhatt AV (1990). Comparison of oral preparations of heroin and methadone to stabilise opiate misusers as inpatients. British Medical Journal, 300, 719–20.
Ghodse AH , Greaves JL & Lynch D (1999). Evaluation of the opioid addiction test in an out-patient drug dependency unit. British Journal of Psychiatry, 175, 158–62.
Ghodse AH , Reed JL & Mack JW (1977). The effect of maternal narcotic addiction on the newborn infant. Psychological Medicine, 7, 667–75.
Ghodse AH , Sheehan M , Stevens B , Taylor C & Edwards G (1978). Mortality among addicts in Greater London. British Medical Journal, 2, 1742–4.
Ghodse AH , Sheehan M , Stevens B , Taylor C & Edwards G (1978). Mortality among addicts in Greater London. British Medical Journal, 2, 1742–4.
Ghodse AH , Sheehan M , Taylor C & Edwards G (1985). Death of drug addicts in the United Kingdom 1967–1981. British Medical Journal, 290, 425–8.
Ghodse AH , Sheehan M , Taylor C & Edwards G (1985). Deaths of drug addicts in the United Kingdom, 1967–1981. British Medical Journal, 290, 425–8.
Ghodse AH , Stapleton J , Edwards G & Edeh J (1987). Monitoring changing patterns of drug dependence in accident and emergency departments. Drug and Alcohol Dependence, 19, 265–9.
Ghodse AH , Stapleton J , Edwards G , Bewley T & A-Samarrai M (1986). A comparison of drug-related problems in London accident and emergency departments, 1975–1982. British Journal of Psychiatry, 148, 658–62.
Ghodse AH , Tregenza G & Li M (1987). Effect of a fear of AIDS on sharing of injection equipment among drug abusers. British Medical Journal, 2, 698–9.
Ghodse AN & Kreek M-J (1998). Resurgence of abuse of amphetamine-type stimulants. Current Opinion in Psychiatry, 11, 245–7.
Ghodse H & Khan I (1988). Psychoactive Drugs: Improving Prescribing Practices. Geneva: WHO.
Ghodse H & Ricaurte GA (2000). Hepatitis C: bad news for substance misusers. Current Opinion in Psychiatry 13, 281–3.
Ghodse H (1995). International policies on addiction. Strategy development and cooperation. British Journal of Psychiatry, 166, 145–8.
Ghodse H (1995). International policies on addiction. Strategy developments and co-operation. British Journal of Psychiatry, 166, 145–8.
Ghodse H (1999). Guiding principles of drug demand reduction: an international response. British Journal of Psychiatry, 175, 310–12.
Ghodse H (1999). Guiding principles of drug demand reduction: an international response. British Journal of Psychiatry, 175, 310–12.
Ghodse H (2000). Doctors and their health. Who heals the healers? In Doctors and Their Health, ed. H Ghodse , S Mann & P Johnson . Sutton, Surrey: Reed Healthcare.
Ghodse H (2007). Report by the International Centre for Drug Policy. Substance Misuse in the Undergraduate Medical Curriculum. London: International Centre for Drug Policy (ISBN: 1 897778 48 1).
Ghodse H (2008). Counterfeit medicines and the unregulated market for drugs. International Psychiatry, 5, 53–4.
Ghodse H (2008). International Drug Control into the 21st Century. Aldershot: Ashgate Publishing.
Ghodse H (2008). International Drug Control into the 21st century. Aldershot: Ashgate Publishing.
Ghodse H (2008). International Drug Control into the 21st Century. Aldershot: Ashgate Publishing.
Ghodse H (ed.) (2005). Addiction at Work. Tackling Drug Use and Misuse in the Workplace. London: Gower.
Ghodse H (ed.) (2005). Addiction at Work. Tackling Drug Use and Misuse in the Workplace. London: Gower.
Ghodse H , Corkery J , Oyefeso A & Schifano F (2008). Drug-Related Deaths in the UK: Annual Report 2008. London: International Centre for Drug Policy, St George's University of London. www.sgul.ac.uk/about-st-georges/divisions/faculty-of-medicine-and-biomedical-sciences/mental-health/icdp/our-work-programmes/Annual%20Report%20Drug%20Deaths%202008.pdf.
Ghodse H , Corkery J , Oyefeso A , Schifano F & Tonia T (2007). Drug-Related Deaths in the UK: Annual Report 2007. London: International Centre for Drug Policy, St George's University of London.
Ghodse H , Corkery J , Oyefeso A , Schifano F , Ahmed K & Naidoo V (2009). Drug-Related Deaths in the UK: Annual Report 2009. London: International Centre for Drug Policy, St George's University of London. www.sgul.ac.uk/about-st-georges/divisions/faculty-of-medicine-and-biomedical-sciences/mental-health/icdp/website-pdfs/np-SADIOth annual report.pdf.
Ghodse H , McNally L , Oyefeso A , et al. (2004). Reduction In Tobacco Addiction Training Manual: A Guide for Health Professionals Providing Smoking Cessation Interventions for Patients in Hospital and Out-patient Setting. London: International Centre for Drug Policy, St George's University of London.
Ghodse H , McNally L , Oyefeso A , et al. (2005). The Provision of Stop Smoking Interventions in General and Psychiatric Hospital Settings: A Service Delivery Toolkit. London: Reduction In Tobacco Addiction, St George's University of London, Ipswich Hospital NHS Trust & Keele University Medical School.
Ghodse H , Myles J & Smith SE (1994). Clonidine is not a useful adjunct to methadone gradual detoxification in opioid addiction. British Journal of Psychiatry, 165, 370–4.
Ghodse H , Oyefeso A & Kilpatrick B (1998). Mortality of drug addicts in the United Kingdom (1967–93). International Journal of Epidemiology, 27, 473–8.
Ghodse H , Oyefeso A & Kilpatrick B (1998). Mortality of drug addicts in the United Kingdom 1967–1993. International Journal of Epidemiology, 27, 473–8.
Ghodse H , Schifano F , Szendrei K , Carver S & Annan J (2007). Herbal Medicine in the Treatment of Addictions. London: International Centre for Drug Policy.
Ghodse H , Taylor DR , Greaves JL , Britten AJ & Lynch D (1995). The opiate addiction test: a clinical evaluation of a quick test for physical dependence on opiate drugs. British Journal of Clinical Pharmacology, 39, 257–9.
Glanz A & Taylor C (1986). Findings of a national survey of the role of general practitioners in the treatment of opiate misuse: extent of contact. British Medical Journal, 293, 427–30.
Glanz A (1994). The fall and rise of the general practitioner. In Heroin Addiction and Drug Policy, ed. J Strang & M Gossop . Oxford: Oxford University Press, pp. 151–66.
Glanz M , Klawansky S , McAullife W & Chalmers T (1997). Methadone vs l-alpha acetylmethadol (LAAM) in the treatment of opiate addiction. A meta-analysis of the randomized controlled trials. American Journal of Addiction, 6, 339–49.
Glass IB & Jackson P (1988). Maudsley Hospital Survey: prevalence of alcohol problems and other psychiatric disorders in a hospital population. British Journal of Addiction, 83, 1105–11.
Glennon RA (1994). Classical hallucinogens: an introductory overview. In Hallucinogens: An Update. NIDA monograph series 146, ed. GC Lin & RA Glennon . Washington, DC: Department of Health and Human Services, pp. 4–32.
Goddard E (1997). Young Teenagers and Alcohol in 1996, vol. 1, England. London: Office for National Statistics.
Goddard E (2008). General Household Survey 2006: Smoking and Drinking among Adults 2006. Newport: Office of National Statistics. Available at: www.statistics.gov.uk.
Gold MS & Johnson CR (1998). Psychological and psychiatric consequences of opiates. In Handbook of Substance Abuse. Neurobehavioural Pharmacology, ed. RE Tarter , RT Ammerman & PJ Ott . New York: Plenum, pp. 363–77.
Goldberg D , Burns S , Taylor A , et al. (2001). Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle/syringe exchange. Scandinavian Journal of Infectious Diseases, 33, 457–61.
Goldstein A (1983). Some thoughts about endogenous opioids and addiction. Drug and Alcohol Dependence, 11, 11–14.
Goldstein MG (1998). Bupropion sustained release and smoking cessation. The Journal of Clinical Psychiatry, 59 (Suppl 4), 66–72.
Gossop M & Strang J (1990). Psychological treatments. In Substance Abuse and Dependence, ed. AH Ghodse & D Maxwell . London: Macmillan Press, pp. 131–48.
Gossop M , Marsden J , Stewart D & Kidd T (2003). The National Treatment Outcome Research Study (NTORS): 4–5 year follow-up results. Addiction, 98, 291–303.
Gossop M , Marsden J , Stewart D & Rolfe A (1999). The National Treatment Outcome Research Study: Changes in Substance Use, Health and Crime. Fourth Bulletin. London: Department of Health.
Gossop M , Marsden J , Stewart D & Rolfe A (1999). Treatment retention and one-year outcomes for residential programmes in England. Drug and Alcohol Dependence, 57, 89–98.
Gossop M , Trakada K , Stewart D & Witton J (2005). Reductions in criminal convictions after addiction treatment: 5-year follow-up. Drug and Alcohol Dependence, 79, 295–302.
Grabowski J (ed.) (1984). Cocaine: Pharmacology, Effects and Treatment Abuse. NIDA research monograph. Rockville, MD: Department of Health and Human Services.
Griffith JD , Rowan-Szal GA , Roark RR , et al. (2000). Contingency management in outpatient methadone treatment: a meta-analysis. Drug and Alcohol Dependence, 58, 55–66.
Griffiths P , Gossop M , Wickenden S , et al. (1997). A transcultural pattern of drug use: qat (khat) in the UK. British Journal of Psychiatry, 170, 282–4.
Grimshaw GM & Stanton A (2008). Smoking cessation services for young people. British Medical Journal, 337, 827–8. DOI: 10.1136/bmj.a1394.
Grinspoon L & Bakalar JB (1981). Coca and cocaine as medicines: a historical review. Journal of Ethnopharmacology, 3, 149–59.
Guindon GE & Boisclair D (2003). H N P Discussion Paper: Economics of Tobacco Control Paper No. 6. Past, Current and Future Trends in Tobacco Use. Geneva: Tobacco Free Initiative, WHO.
Hall W , Solowij N & Lemon J (1994). The Health and Psychological Consequences of Cannabis Use. National drug strategy monograph series 25. Canberra: Australian Government Publishing Service.
Hansbro J , Bridgewood A , Morgan A & Hickman M (1996). Health in England: What People Know, What People Think, What People Do. London: HMSO.
Harkin AM , Anderson P & Lehto J (1995). Alcohol in Europe: a Health Perspective. Copenhagen: WHO Regional Office for Europe.
Harris HE , Ramsay ME , Heptonstall J , et al. (2000). The HCV National Register: towards informing the natural history of hepatitis C infection in the UK. Journal of Viral Hepatitis, 7, 420–7.
Hartnoll RL , Mitcheson MC , Battersby A , et al. (1980). Evaluation of heroin maintenance in a controlled trial. Archives of General Psychiatry, 37, 877–84.
Haupt HA & Rovere GD (1984). Anabolic steroids: a review of the literature. American Journal of Sports Medicine, 12, 469–84.
Hawks D , Mitcheson M , Ogborne A & Edwards G (1969). Abuse of methylamphetamine. British Medical Journal, 2, 715–21.
Hawks RL (1982). The constituents of cannabis and the disposition and metabolism of cannabinoids. In The Analysis of Cannabinoids in Biological Fluids, ed. RL Hawks . NIDA research monograph 42. Rockville, MD: Department of Health and Human Services, pp. 125–37.
Hay H , Gannon M , MacDougal J , et al. (2008). National and Regional Estimates of the Prevalence of Opiate Use and/or Crack Cocaine Use 2006/07: A Summary of Key Findings. Research Report 9. November 2008. London: Home Office Research Development and Statistics Directorate. www.homeoffice.gov.uk/rds/pdfs08/horr09.pdf.
Healey A , Knapp M , Astin J , et al. (1998). Economic burden of drug dependency. Social costs incurred by drug users at intake to the National Treatment Outcome Research Study. British Journal of Psychiatry, 173, 160–5.
Health Education Authority (1996). Drug Realities: National Drugs Campaign Survey: Summary of Key Findings. London: Health Education Authority.
Health Protection Agency (2007). Hepatitis C in England. The Health Protection Agency Annual Report 2007. December 2007. London: Health Protection Agency, Centre for Infections. www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1204100441645.
Health Protection Agency (2007). Hepatitis C in England. The Health Protection Annual Report 2007. London: HPA. Available at: www.hpa.org.uk/publications/PublicationDisplay.asp?PublicationID=116.
Health Protection Agency (2008). Injecting drug use: HIV diagnoses surveillance tables – data to the end of December 2007. 4 April 2008. London: Health Protection Agency. www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1207821645553.
Health Protection Agency (2008). United Kingdom HIV New Diagnoses to End of June 2008. 21 August 2008. London: Health Protection Agency. www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1224574905324.
Health Protection Agency (date accessed: 29 June 2009). Unlinked Anonymous Survey of Injecting Drug Users (IDUs); data to the end of 2007. Available at: www.hpa.org.uk.
Henningfield JE & Jasinski DR (1988). Pharmacologic basis for nicotine replacement. In Nicotine Replacement, ed. OF Pomerleau & CS Pomerleau . New York: Alan R. Liss, pp. 35–61.
Hickman M , Hope V , Brady T , et al. (2007). Hepatitis C (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. Journal of Viral Hepatitis, 14, 645–52.
Hickman M , McDonald T , Judd A , et al. (2008). Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. Journal of Viral Hepatitis, 15, 250–4.
Higgins ST , Alessi SM & Dantona RL (2002). Voucher-based incentives: a substance abuse treatment innovation. Addictive Behaviour, 27, 887–910.
HM Government (2005). The Hazardous Waste (England and Wales) Regulations (2005). Statutory Instrument No. 894. London: The Stationary Office. www.opsi.gov.uk/si/si2005/20050894.htm.
HM Government (2007). Safe. Sensible. Social. The Next Steps in the National Alcohol Strategy. 5 June 2007. London: Department of Health, Home Office, Department for Education and Skills and Department for Culture, Media and Sport. Available at: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_075218.
HM Government (date accessed: 30 June 2009). Every Child Matters. Change for Children. London: Department for Skills and Education. www.everychildmatters.gov.uk/.
HM Prison Service (1998). Tackling Drugs in Prison: The Prison Service Drug Strategy. London: HM Prison Service.
Hoare J & Flatley J (2008). Drug Misuse Declared: Findings from the 2007/08 British Crime Survey. Statistical Bulletin 13/08. 30 October 2008. London: Home Office Research Development and Statistics Directorate. www.homeoffice.gov.uk/rds/pdfs08/hosb1308.pdf.
Hobbs WR , Rall TW & Verdoorn TA (1996). Hypnotics and sedatives: ethanol. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn, ed. JG Hardman & LE Limbird . New York: McGraw-Hill.
Hobbs WR , Rall TW & Verdoorn TA (1996). Hypnotics and sedatives: ethanol. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn, ed. JG Hardman & LE Limbird . New York: McGraw-Hill.
Hodgson R , Alwyn T , John B , Thom B & Smith A (2002). The FAST Alcohol Screening Test. Alcohol & Alcoholism, 37, 61–6.
Home Office (2002). Updated Drug Strategy 2002. 3 December 2002. London: Home Office.
Home Office (2008). Drugs: Protecting Families and Communities – 2008. 27 February 2008. London: Home Office. Available at: http://drugs.homeoffice.gov.uk/publication-search/drug-strategy/drug-strategy-2008?view=Standard&pubID=531716.
Home Office (published annually up to 1990). Statistics of the Misuse of Drugs in the United Kingdom. London: Home Office.
Houtsmuller EJ , Walsh SL , Schuh KJ , et al. (1998). Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance. Journal of Pharmacology and Experimental Therapeutics, 285, 387–96.
Hubbard RI , Craddock G , Flynn P , et al. (1997). Overview of 1-year outcomes in the Drug Abuse Treatment Outcomes Study (DATOS). Psychology of Addictive Behaviour, 11, 261–78.
Hutchinson SJ , Roy KM , Wadd S , et al. (2006). Hepatitis C virus infection in Scotland: epidemiological review and public health challenges. Scottish Medical Journal, 51, 8–15.
Idanpaan-Heikkila J , Ghodse AH & Khan I (eds.) (1987). Psychoactive Drugs and Health Problems. Helsinki: National Board of Health.
International Centre for Drug Policy (2005). Reduction in Tobacco Addiction, Final Report to the Department of Health. London: International Centre for Drug Policy, St George's University of London.
International Narcotics Control Board (1998). Report of the International Narcotics Control Board for 1997. New York: United Nations Publications.
International Narcotics Control Board (2000). Narcotic Drugs Report 2000: Estimated World Requirements for 2001 – Statistics for 1999. New York: United Nations Publications. Available at: www.incb.org/incb/en/ narcotic_drugs_2000.html.
International Narcotics Control Board (2000). Report of the International Narcotics Control Board for 1999. New York: United Nations Publications (sales no. E.00.XI.1).
International Narcotics Control Board (2001). Report of the International Narcotics Control Board for 2000. New York: United Nations Publications (sales no. E.01.XI.1).
International Narcotics Control Board (2005). Narcotic Drugs Report 2004: Estimated World Requirements for 2005 – Statistics for 2003. New York: United Nations Publications. Available at: www.incb.org/incb/en/ narcotic_drugs_2004.html.
International Narcotics Control Board (2008). Narcotic Drugs Report 2007: Estimated World Requirements for 2008 – Statistics for 2006. New York: United Nations Publications. www.incb.org/pdf/technical-reports/narcotic- drugs/2007/narcotic_drugs_2007_final.pdf.
International Narcotics Control Board (2008). Narcotic Drugs. Estimated World Requirements for 2008. Statistics for 2007. Vienna: United Nations.
International Narcotics Control Board (2008). Psychotropic Substances Report 2007: Statistics for 2006 – Assessments of Annual Medical and Scientific Requirements. New York: United Nations Publications. www.incb.org/pdf/e/tr/psy/2007/PSY%2007–88433_Ebook.pdf.
International Narcotics Control Board (2008). Report of the International Narcotics Control Board for 2007. New York: United Nations Publications (sales no. E.08.XI.1).
International Narcotics Control Board (2008). Report of the International Narcotics Control Board for 2007. New York: United Nations Publications. www.incb.org/pdf/annual-report/2007/en/annual-report-2007.pdf.
International Narcotics Control Board (2008). Report of the International Narcotics Control Board for 2007. New York: United Nations.
International Narcotics Control Board (2009). Report of the International Narcotics Control Board for 2008. New York: United Nations Publications.
International Narcotics Control Board (2009). Report of the International Narcotics Control Board for 2008. New York: United Nations Publications. www.incb.org/pdf/annual-report/2008/en/AR_08_English.pdf.
International Narcotics Control Board (date accessed: 30 June 2009). Home page of the INCB. www.INCB.org.
International Narcotics Control Board (date accessed: 30 June 2009). Home page of the INCB. www.INCB.org.
Jacobson JL & Jacobson SW (1994). Prenatal alcohol exposure and neurobehavioural development: where is the threshold? Alcohol and Health Research World, 18, 30–6.
Jaffe J , Petersen R & Hodgson R (1980). Addiction, Issues and Answers. London: Harper & Row.
Jaffe JH & Martin WR (1991). Opioid analgesics and antagonists. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edn, ed. AG Gilman , AS Nies & TW Rall . New York: Pergamon.
Jaffe JH (1991). Drug addiction and drug abuse. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edn, ed. AG Gilman , AS Nies & TW Rall . New York: Pergamon.
Jaffe JH (2001). Injectable opiate maintenance in the United Kingdom: a view from the United States. Addiction, 96, 557–60.
Jameson A , Glanz A & Macgregor S (1984). Dealing with Drug Misuse. Crisis Intervention in the City. London: Tavistock.
Jasinski D , Fudala PJ & Johnson RE (1989). Sublingual versus subcutaneous buprenorphine in opiate abusers. Clinical Pharmacology and Therapeutics, 45, 513–19.
Johanson C-E , Balster RL & Bonese K (1976). Self-administration of psychomotor stimulant drugs: the effects of unlimited access. Pharmacology, Biochemistry & Behaviour, 4, 45–51.
Johns A (2000). Sick doctors and the law. In Doctors and their Health, ed. H Ghodse , S Mann & P Johnson . Sutton, Surrey: Reed Healthcare.
Johns A (2001). Psychiatric effects of cannabis. British Journal of Psychiatry, 178, 116–22.
Johnson BA (1990). Psychopharmacological effects of cannabis. British Journal of Hospital Medicine, 43, 114–22.
Johnson RE , Jaffe JH & Fudala PJ (1992). A controlled trial of buprenorphine treatment for opioid dependence. JAMA, 267, 2750–5.
Jones JM (2006). Smoking Habits Stable; Most Would Like to Quit. Gallup News Service, July 18, 2006. www.gallup.com/poll/23791/Smoking-Habits-Stable-Most-Would-Like-Quit.aspx.
Jones KL & Smith DW (1973). Recognition of the fetal alcohol syndrome in early infancy. The Lancet, 2, 999–1001.
Judd A , Hickman M , Jones S , et al. (2005). Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ, 330, 24–5.
Juergens SM (1993). Benzodiazepines and addiction. Psychiatric Clinics of North America, 16, 75–86.
Kahn A , Mumford JP , Rogers GA & Beckford H (1997). Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug and Alcohol Dependence, 44, 57–61.
Kalix P (1987). Khat: scientific knowledge and policy issues. British Journal of Addiction, 82, 47–53.
Kalix P (1990). Pharmacological properties of the stimulant khat. Pharmacology & Therapeutics, 48, 397–416.
Kaltenbach K & Finnegan L (1997). Children of maternal substance misusers. Current Opinion in Psychiatry, 10, 220–4.
Kandel D , Yamaguchi K & Chen K (1992). Stages of progression in drug involvement from adolescence to adulthood: further evidence for the gateway theory. Journal of Studies on Alcohol, 53, 447–57.
Kaner EF , Beyer F , Dickinson HO , et al. (2007). Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database of Systematic Reviews (Online), 2, CD004148.
Kaplan SR & Razin AM (1978). The psychological substrate of self-help groups. Journal of Operational Psychiatry, 9, 57.
Kellogg SH , Burns M , Coleman P , et al. (2005). Something of value: the introduction of contingency management interventions into the New York City Health and Hospital Addiction Treatment Service. Journal of Substance Abuse Treatment, 28, 57–65.
Kennedy J , Teague J , Rrokaw W & Cooney E (1983). A medical evaluation of the use of qat in North Yemen. Social Science and Medicine, 17, 783–93.
Kessler R , Crum RM , Warner LA , et al. (1997). Lifetime co-occurrence of DSM-III-R psychiatric disorders in the United States. Archives of General Psychiatry, 54, 313–21.
Kessler RI (1995). Epidemiology of psychiatric comorbidity. In Textbook of Psychiatric Epidemiology, ed. M Tsuang , M Tohen & GEP Zahner . New York: John Wiley & Sons, Inc.
Kilpatrick B , Howlett M , Sedgwick P & Ghodse AH (2000). Drug use, self report and urinalysis. Drug & Alcohol Dependence, 58, 111–16.
King GR & Ellingwood EH (1992). Amphetamines and other stimulants. In Substance Abuse: A Comprehensive Textbook, 2nd edn, ed. JH Lowinson , P Ruiz , RD Millman & JG Langrod . Baltimore, MD: Williams & Wilkins, pp. 247–70.
King MB , Gabe J , Williams P & Rodrigo EK (1990). Long term use of benzodiazepines: the views of patients. British Journal of General Practice, 40, 194–6.
Kirchmayer U , Davoli M , Verster AD , et al. (2002). A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction, 97, 1241–9.
Kleber HD , Riordan CE , Rounsaville BJ , et al. (1985). Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry, 42, 391–4.
Klee H & Morris J (1995). The role of needle exchanges in modifying sharing behaviour: cross-study comparisons 1989–1993. Addiction, 90, 1635–45.
Klein C , di Menza S , Arfken C & Schuster CR (2002). Interaction effects of treatment setting and client characteristics on retention and completion. Journal of Psychoactive Drugs, 34, 39–50.
Koob GF & LeMoal M (2005). Neurobiology of Addiction. London: Elsevier.
Koob GF (1992). Neural mechanisms of drug reinforcement. Annals of the New York Academy of Science, 654, 171–91.
Kouimtsidis C , Reynolds M , Hunt M , et al. (2003). Substance use in the general hospital. Addictive Behaviours, 28, 483–99.
Krausz M (1996). Old problems – new perspectives. European Addiction Research, 2, 1–2.
Kreek MJ (1997). Opiate and cocaine addictions: challenge for pharmacotherapies. Pharmacology, Biochemistry and Behaviour, 57, 551–69.
Lader M (1983). Dependence on benzodiazepines. Journal of Clinical Psychiatry, 44, 121–7.
Landry DW (1997). Immunotherapy for cocaine addiction. Scientific American 276, 42–5.
Landry M (1995). Overview of Addiction Treatment Effectiveness. Rockville, MD: Office of Applied Studies, SAMHSA.
Lasser K , Boyd JW , Woolhandler S , et al. (2000). Smoking and mental illness: a population-based prevalence study. Journal of the American Medical Association, 284, 2606–10.
League of Nations (1912). International Opium Convention, 1912, Treaty series, vol. VIII, p. 187. http://treaties.un.org/Pages/ViewDetailsIV.aspx?&src=TREATY &mtdsg_no=VI~2&chapter=6&Temp=mtdsg4&lang=en.
League of Nations (1925). International Opium Convention, 1925, Treaty series, vol. LXXXI, p. 317.
League of Nations (1931). Convention for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs, 1931, Treaty series, vol. CXXXIX, p. 301.
League of Nations (1936). Convention for the Suppression of the Illicit Traffic in Dangerous Drugs, 1936, Treaty series, vol. CXCVIII, p. 299.
Lehmann AF , Meyers CP & Corty E (1989). Classification of patients with psychiatric and substance abuse syndromes. Hospital and Community Psychiatry, 40, 1019–25.
Leon DA & McCambridge J (2006). Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. The Lancet, 367, 52–6.
Leon DA (2001). Alcohol: the changing face of a perennial problem. International Journal of Epidemiology, 30, 653–4.
Lewis A , Miller JH & Lea RA (2006). Monoamine oxidase and tobacco dependence. Neurotoxicology, 28, 182–95.
Lewis R , Hartnoll R , Bryer S , Daviaud E & Mitcheson M (1985). Scoring smack: the illicit heroin market in London 1980–1983. British Journal of Addiction, 80, 281–90.
Libman H and Witzburg RA (1993). HIV Infection: A Clinical Manual, 2nd edn. Boston: Littlebrown.
Liddle HA & Dakof GA (1995). Efficacy of family therapy for drug abuse: promising but not definitive. Journal of Marital Family Therapy, 21, 511–43.
Lima MS , Reisser AA , Soares BG & Farrell M (2003). Antidepressants for cocaine dependence. Cochrane Database of Systematic Reviews (Online), 2, CD002950. PMID: 12804445.
Linehan MM (1995). Understanding Borderline Personality Disorder: The Dialectic Approach Program Manual. New York: Guilford Press.
Linszen DH , Dingemans PM & Lenior ME (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry, 51, 273–9.
Lloyd GG & Guthrie E (eds.) (2007). Handbook of Liaison Psychiatry. Cambridge: Cambridge University Press.
London M (2001). Prevention of substance misuse. Current Opinion in Psychiatry, 14, 207–11.
Lord President of the Council, and Leader of the House of Commons, Secretary of State for the Home Department, Secretary of State for Health, Secretary of State for Education, and the Paymaster General (1995). Tackling Drugs Together: A Strategy for England 1995–98. London: HMSO.
Luborsky L (2000). A pattern-setting therapeutic alliance study revisited: “helping alliances in psychotherapy”. Psychotherapy Research, 10, 17–29.
Luborsky L , McLellan AT & Woody GE (1985). Therapist success and its determinants. Archives of General Psychiatry, 42, 602–11.
Mackay J & Erikson M (2002). The Tobacco Atlas. Geneva: WHO.
Madden S (1990). Effects of drugs of dependence. In Substance Abuse and Dependence, ed. AH Ghodse & D Maxwell . London: Macmillan Press, pp. 30–52.
Magura S , Freeman RC , Siddiqi Q & Lipton DS (1992). The validity of hair analysis for detecting cocaine and heroin use among addicts. International Journal of the Addictions, 27, 51–6.
Mangtani P , Kovats S & Hall A (1995). Hepatitis B vaccination policy in drug treatment services. British Medical Journal, 311, 1500.
Manns MP , McHutchison JG , Gordon SC , et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. The Lancet. 358, 958–65.
Margolin A , Avants SK & Kosten TR (1996). Abstinence symptomatology associated with cessation of chronic cocaine abuse among methadone-maintained patients. American Journal of Drug and Alcohol Abuse, 22, 377–88.
Marks J (1988). Techniques of benzodiazepine withdrawal in clinical practice. A consensus workshop report. Medical Toxicology, 3, 324–33.
Marlatt GA & Donovan DM (eds.) (2005). Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. 2nd edn. New York: Guilford Press.
Marlatt GA & George W (1984). Relapse prevention: introduction and overview of the model. British Journal of Addiction, 79, 261–73.
Marrow LP , Overton PG , Brain PF & Clark D (1999). Encounters with aggressive conspecifics enhance the locomotor activating effect of cocaine in the rat. Addiction Biology, 4, 437–41.
Marsch LA (1998). The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction, 93, 515–32.
Matheï C , Buntinx F & van Damme P (2002). Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. Journal of Viral Hepatitis, 9, 157–73.
Mathers CD & Loncar D (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine, 3, e442. Available at: www.plosmedicine.org.
Mathers DC & Ghodse AH (1992). Cannabis and psychotic illness. British Journal of Psychiatry, 161, 648–53.
Mathers DC , Ghodse AH , Cann AW & Scott SA (1991). Cannabis use in a large sample of acute psychiatric admissions. British Journal of Addiction, 86, 779–84.
Mattick RP & Heather N (1993). Developments in cognitive and behavioural approaches to substance misuse. Current Opinion in Psychiatry, 6, 424–9.
Maxwell C , Kinver A & Phelps A (2007). Scottish Schools Adolescent Lifestyle and Substance Use Survey (SALSUS) – 2006 National Report. 29 May 2007. Edinburgh: ISD Scotland. www.drugmisuse.isdscotland.org/publications/local/SALSUS_2006.pdf.
Maxwell D (1990). Clinical complications of substance abuse. In Substance Abuse and Dependence, ed. AH Ghodse & D Maxwell . Macmillan Press: London, pp. 176–203.
Mayfield D , McLeod G & Hall P (1974). The CAGE questionnaire: validation of a new alcoholism screening instrument. American Journal of Psychiatry, 131, 1121–3.
McCoy CB , Metsch LR , Inciardi JA , et al. (1996). Sex drugs and the spread of HIV/AIDS in Belle Glade, Florida. Medical Anthropology Quarterly, 10, 83–93.
McEvoy AW , Kitchen ND & Thomas DGT (2000). Intracerebral haemorrhage in young adults: the emerging importance of drug misuse. British Medical Journal, 320, 1322–4.
McKay JR , Cacciola JS , McLellan AT , Alterman AI & Wirtz PW (1997). An initial evaluation of the psychosocial dimensions of the American Society of Addiction Medicine criteria for inpatient versus intensive outpatient substance abuse rehabilitation. Journal of Studies on Alcohol, 58, 239–52.
McKim WA (1997). Drugs and Behavior: An Introduction to Behavioral Pharmacology, 3rd edn. Upper Saddle River, NJ: Prentice-Hall.
McLellan AT , Arndt I , Metzger DS , Woody GE & O'Brien CP (1993). The effects of psychosocial services in substance abuse treatment. JAMA, 269, 1953–9.
McLellan AT , Woody GE , Luborsky L & O'Brien CP (1988). Is the counsellor an ‘active ingredient’ in substance abuse treatment? Journal of Nervous and Mental Disease, 176, 423–30.
McNally L , Oyefeso A , Annan J , et al. (2006). A survey of staff attitudes to smoking-related policy and intervention in psychiatric and general health care settings. Journal of Public Health (Oxford), 28, 192–6.
McNeill A (2001). Smoking and Mental Health – A Review of the Literature. London: SmokeFree London Programme.
Meltzer H , Gill B , Petticrew M , et al. (1995). Economic Activity and Social Functioning of Adults with Psychiatric Disorders. OPCS Surveys of Psychiatric Morbidity in Great Britain Report 3. London: HMSO.
Merton RK (1957). Social Theory and Social Structure, rev. edn. New York: The Free Press of Glencoe.
Messina N , Wish E & Nemes S (2000). Predictors of treatment outcomes in men and women admitted to a therapeutic community. American Journal of Drug and Alcohol Abuse, 26, 207–27.
Miczek KA & Mutschler NH (1996). Activational effects of social stress on IV cocaine self-administration. Psychopharmacology, 128, 256–64.
Middleman AB & Du Rant RH (1996). Anabolic steroid use and associated health risk behaviours. Sports Medicine, 21, 251–5.
Middleton RM & Kirkpatrick MB (1993). Clinical use of cocaine: a review of the risks and benefits. Drug Safety, 9, 212–17.
Miller WR & Rollnick S (2002). Motivational Interviewing. Preparing People to Change Addictive Behaviour. New York: Guilford Press.
Miller WR (1996). Motivational interviewing: research, practice and puzzles. Addictive Behaviors, 21, 835–42.
Ministry of Health, and Department of Health for Scotland (1961). Drug Addiction: Report of the Interdepartmental Committee. London: HMSO.
Ministry of Health, and Department of Health for Scotland (1965). Drug Addiction: The Second Report of the Interdepartmental Committee. London: HMSO.
Mino Y , Shigemi J , Otsu T , et al. (2000). Does smoking cessation improve mental health? Psychiatry and Clinical Neurosciences, 54, 169–72.
Mitchell J & Vierkant AD (1991). Delusions and hallucinations of cocaine abusers and paranoid schizophrenics: a comparative study. Journal of Psychology, 125, 301–10.
Moner SE (1996). Acupuncture and addiction treatment. Journal of Addictive Behaviour, 15, 79–100.
Morgan D , Grant KA , Gage HD , et al. (2002). Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. Nature Neuroscience, 5, 169–74.
Morgan JR (1990). Treatment and management. In Substance Abuse and Dependence, ed. AH Ghodse & D Maxwell . London: Macmillan Press, pp. 98–130.
Mott J (1981). Criminal involvement and penal response. In Drug Problems in Britain: A Review of Ten Years, ed. G Edwards & C Busch . London: Academic Press.
Mott J (1981). Criminal involvement and penal response. In Drug Problems in Britain; a Review of Ten Years, ed. G Edwards & C Busch . London: Academic Press.
Moyer A , Finney JW , Swearingen CE & Vergun P (2002). Brief interventions for alcohol problems: a meta-analytic review of controlled investigations in treatment-seeking and non-treatment-seeking populations. Addiction, 97, 279–92.
Mueser KT , Drake RE & Wallach MA (1998). Dual diagnosis: a review of etiological theories. Addictive Behaviour, 23, 7217–34.
Murphy R & Roe S (2007). Drug Misuse Declared: Findings from the 2006/07 British Crime Survey: England and Wales. December 2007. London: Home Office Research Development and Statistics Directorate. www.homeoffice.gov.uk/rds/pdfs07/hosb1807.pdf.
Murray R , Ghodse AH , Harris C , Williams D & Williams P (eds.) (1981). The Misuse of Psychotropic Drugs. London: Gaskell, Royal College of Psychiatrists.
Murray RM (1973). Dependence on analgesics in analgesic nephropathy. British Journal of Addiction, 68, 265–72.
Mwenda L (2005). Drug Offenders in England and Wales 2004. Home Office Statistical Bulletin 23/05. December 2005. London: Home Office Research Development and Statistics Directorate. www.homeoffice.gov.uk/rds/pdfs05/hosb2305.pdf.
Narcotics Anonymous (1987). Narcotics Anonymous, 4th edn. Van Nuys, CA: World Service Office.
National Assembly for Wales (2000). Tackling Substance Misuse in Wales: A Partnership Approach. April 2000. Cardiff: The National Assembly for Wales. http://new.wales.gov.uk/dsjlg/publications/commmunitysafety/ substancemisusestrategy/strategye.pdf?lang=en.
National Institute for Clinical Excellence (NICE) (2000). Guidance on the Use of Methylphenidate for ADHD in Childhood. Technology appraisal guidance 13. London: NICE, www.nice.org.uk.
National Institute for Health and Clinical Excellence (2007) Drug Misuse. Opioid Detoxification. National Clinical Practice Guideline number 52. London: NICE.
National Institute for Health and Clinical Excellence (2007). Drug Misuse. Psychosocial Interventions. National Clinical Practice Guideline number 51. London: NICE.
National Institute for Health and Clinical Excellence (2007). Methadone and Buprenorphine for the Management of Opioid Dependence. NICE technology appraisal 114. London: NICE.
National Institute for Health and Clinical Excellence (2007). Naltrexone for the Management of Opioid Dependence. NICE technology appraisal 115. London: NICE.
National Institute for Health, and Clinical Excellence (2006). Peginterferon Alfa and Ribavirin for the Treatment of Mild Chronic Hepatitis. NICE technology appraisal guidance 106. London: NICE. Available at: www.nice.org.uk.
National Institute for Health, and Clinical Excellence (2007). Drug Misuse. Opioid Detoxification. National Clinical Practice Guideline Number 52. London: NICE.
National Institute for Health, and Clinical Excellence (2007). Drug Misuse. Psychosocial Interventions. National Clinical Practice Guideline number 51. London: NICE.
National Institute for Health, and Clinical Excellence (2007). Drug Misuse: Psychosocial Interventions. NICE Clinical Guideline 51. London: NICE.
National Institute for Health, and Clinical Excellence (2007). Methadone and Buprenorphine for the Management of Opioid Dependence. NICE technology appraisal 114. London: NICE.
National Institute for Health, and Clinical Excellence (2007). Naltrexone for the Management of Opioid Dependence. NICE technology appraisal 115. London: NICE.
National Institute for Health, and Clinical Excellence (2007). Varenicline for Smoking Cessation. NICE Technology Appraisal Guidance 123. London: NICE. Available at: www.nice.org.uk/TA123.
National Institute for Health, and Clinical Excellence (2008). Entecavir for the Treatment of Chronic Hepatitis B. NICE technology appraisal guidance 153. London: NICE. www.nice.org.uk/nicemedia/pdf/TA153Guidance.doc.
National Institute on Drug Abuse (1997). Drug Abuse Prevention for At-Risk Individuals. Rockville, MD: US National Institutes of Health.
National Institute on Drug Abuse (1998). Assessing Drug Abuse Within and Across Communities. NIH publication 98–3614. Rockville, MD: Department of Health and Human Services.
National Institute on Drug Abuse (2003). Preventing Drug Use among Children and Adolescents. A Research-Based Guide, 2nd edn. Maryland: National Institutes of Health.
National Institute on Drug Abuse (date accessed: 30 June 2009). Drug Abuse Treatment Outcome Studies, Background: Summaries of DARP and TOPs Findings. www.datos.org/background.html.
National Treatment Agency for Substance Abuse (2006). Findings of a Survey of Needle Exchanges in England. London: NTA. Available at: www.nta.nhs.uk.
National Treatment Agency for Substance Misuse (2002). Models of Care for Treatment of Adult Drug Misusers – Framework for Developing Local Systems of Effective Drug Misuse Treatment in England. October 2002. London: National Treatment Agency for Substance Misuse. www.nta.nhs.uk/publications/documents/ nta_modelsofcare1_2002_moc1.pdf.
National Treatment Agency for Substance Misuse (2002). Models of Care for Treatment of Drug Misusers: Promoting Quality, Efficiency and Effectiveness in Drug Misuse Treatment Services in England. October 2002. London: National Treatment Agency for Substance Misuse. www.nta.nhs.uk/publications/documents/nta_modelsofcare2_2002_moc2.pdf.
National Treatment Agency for Substance Misuse (2006). Models of Care for Treatment of Adult Drug Misusers: Update 2006. July 2006. London: National Treatment Agency for Substance Misuse. www.nta.nhs.uk/publications/documents/nta_modelsofcare_update_ 2006_moc3.pdf.
National Treatment Agency for Substance Misuse (2008). Statistics from the National Drug Treatment Monitoring System (NDTMS) 1 April 2007 – 31 March 2008. September 2008. London: National Treatment Agency for Substance Misuse. www.nta.nhs.uk/areas/facts_and_figures/0708/docs/ndtms_annual_report_2007_ 08_011008.pdf.
Newman RG (1979). Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. The Lancet, 2, 485–8.
Northern Ireland Office (1999). Drug Strategy for Northern Ireland. August 1999. Belfast: Northern Ireland Office.
Nuffield Institute for Health, Centre for Health Economics, Royal College of Physicians (1993). Brief interventions and alcohol use. Effective Health Care, 1, 1–14.
O'Brien CP (1996). Drug addiction and drug abuse. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn, ed. JG Hardman & LE Limbird . New York: McGraw-Hill.
Observatoire Français des Drogues et des Toxicomanies (2007). 2007 National Report (2006 Data) to the EMCDDA by the Reitox National Focal Point. France: New Developments, Trends and in-depth Information on Selected Issues – English Version. Paris: Observatoire Français des Drogues et des Toxicomanies (OFDT). www.emcdda.europa.eu/attachements.cfm/att_61194_ EN_NR2007France.pdf.
Office for National Statistics (2007). Deaths related to drug poisoning: England and Wales, 1993–2005. Health Statistics Quarterly, Spring, 33, 82–8. www.statistics.gov.uk/downloads/theme_health/hsq33web.pdf.
Office of Applied Statistics (2008). 2003 National Survey on Drug Use & Health. Research Triangle Park, NC: US Department of Health & Human Services. Available at: www.oas.samhsa.gov/NHSDA/2k3tabs/LOTSect1pe.htm.
Office of Applied Studies (2007). Drug Abuse Warning Network, 2005: National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-29, DHHS Publication No. (SMA) 07–4256, March 2007. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies. http://roar.nevadaprc.org/resources/docs/0000/0149/Drug_Abuse_Warning_Network__2005.pdf.
Office of National Statistics (1998). Living in Britain: Results from the 1996 General Household Survey. London: The Stationery Office.
Office of National Statistics (2007). Statistics on Smoking: England, 2007. London: The Information Centre, ONS. Available at: www.ic.nhs.uk.
Ofori-Adjei D , Casswell S , Drummond DC , et al. (2007). World Health Organization Expert Committee on Problems Related to Alcohol Consumption, Second Report. Geneva: WHO.
Oppenheim GB , Wright JE , Buchanan J & Biggs L (1973). Outpatient treatment of narcotic addiction: who benefits? British Journal of Addiction, 68, 37–44.
Oppenheimer E , Tobutt C , Taylor C & Andrew T (1994). Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction, 89, 1299–308.
Orford J (1985). Excessive Appetites: A Psychological View of Addiction. Chichester: John Wiley & Sons, Ltd.
Orford J (2001). Excessive Appetites: a Psychological View of Addictions, 2nd edn. New York: John Wiley & Sons Inc.
Orford J , Templeton L , Patel A , Velleman R & Copello A (2007). Qualitative study of a controlled family intervention in primary care: II The views of primary health care professionals. Drugs: Education, Prevention and Policy, 14, 117–35.
Oyefeso A (1995). Psychological, social and behavioural correlates of substance use and misuse. Current Opinion in Psychiatry, 8, 184–8.
Oyefeso A , Ghodse H , Clancy C & Corkery JM (1999). Suicide among drug addicts in the UK. British Journal of Psychiatry, 175, 277–82.
Pétursson H & Lader M (1984). Dependence on Tranquillizers. New York: Oxford University Press.
Pétursson H (1994). The benzodiazepine withdrawal syndrome. Addiction, 89, 1455–9.
Parker H & Bottomley T (1996). Crack-Cocaine and Drugs-Crime Careers. London: Home Office Publications Unit.
Pasco JA , Williams LJ , Jacka NN , et al. (2008). Tobacco smoking as a risk factor for major depressive disorder: population based study. British Journal of Psychiatry, 193, 322–6.
Passetti F , Jones G , Chawla K , Boland B & Drummond DC (2008). Pilot study of assertive community treatment methods to engage alcohol-dependent individuals. Alcohol and Alcoholism, 43, 451–5.
Pasternak GW (1993). Pharmacological mechanisms of opioid analgesics. Clinical Neuropharmacology, 16, 1–18.
Patterson MA (1975). Addictions Can be Cured. The Treatment of Drug Addiction by Neuro-electric Stimulation. Berkhamsted: Lion Publishing.
Peachey JE & Loh E (1994). Validity of alcohol and drug assessment. Current Opinion in Psychiatry, 7, 252–8.
Pert CB & Snyder SH (1973). Opiates receptor: demonstration in nervous tissue. Science, 179, 1011–14.
Peto R , Lopez AD , Boreham J , et al. (1996). Mortality from smoking worldwide. British Medical Bulletin, 52, 12–21.
Pittman DJ (1994). Substance misuse prevention, health promotion, and health education. Current Opinion in Psychiatry, 7, 269–73.
Plant M & Plant M (1992). Risk-Takers. Alcohol Drugs Sex and Youth. London: Tavistock/Routledge.
Platt JJ & Metzer D (1985). The role of employment in the rehabilitation of heroin addicts. In Progress in the Development of Cost-Effective Treatment of Drug Abusers. NIDA research monograph series 58, ed. RS Ashery . Rockville, MD: Department of Health and Human Services, pp. 111–21.
Platt JJ (1986). Heroin Addiction: Theory, Research and Treatment, 2nd edn. Malabar: Robert E Krieger.
Porter S & Ghodse AH (1996). Treatment of substance misuse problems in general practice. In General Practice National Association of Fundholding Practices Yearbook. Thornton Heath: Scorpio Publishing, pp. 318–21.
Powell J , Bradley B & Gray J (1992). Classical conditioning and cognitive determinants of subjective craving for opiates: an investigation of their relative contributions. British Journal of Addictions, 87, 1133–44.
Power R (1994). Drug trends since 1968. In Heroin Addiction and Drug Policy, ed. J Strang & M Gossop . Oxford: Oxford University Press, pp. 29–39.
Preble E & Casey JJ Jr (1969). Taking care of business: the heroin user's life on the street. The International Journal of the Addictions, 4, 1–24.
Prendergast ML , Podus D , Chang E & Urada D (2002). The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies. Drug and Alcohol Dependence, 67, 53–72.
Prime Minister's Strategy Unit (2004). Alcohol Harm Reduction Strategy for England. London: PMSU.
Prime Minister's Strategy Unit (2004). Alcohol Harm Reduction Strategy for England. London: PMSU.
Prime Minister's Strategy Unit (2004). Alcohol Harm Reduction Strategy for England. March 2004. London: PMSU. www.cabinetoffice.gov.uk/media/cabinetoffice/strategy/assets/caboffce%20alcoholhar.pdf.
Prochaska JO & DiClemente CC (1986). Toward a comprehensive model of change. In Treating Addictive Behaviors: Process of Change, ed. WR Miller & N Healther . New York: Plenum Press, pp. 3–27.
Project MATCH Research Group (1997). Matching alcohol treatments to client heterogeneity: posttreatment outcomes. Journal of Studies on Alcoholism. 58, 7–29.
Ramsay SE , Neal KR & the Trent Hepatitis C Study Group (2005). Mortality in a cohort of hepatitis C patients. Clinical Microbiology and Infection, 11 (Suppl 2), 15.
Ramsey J , Taylor J , Anderson R , & Flanagan RJ (1995). Volatile substance abuse in the United Kingdom. In Epidemiology of Inhalant Abuse: An International Perspective. NIDA research monograph 148, ed. N Kozel , Z Sloboda & M De La Rosa . Rockville, MD: Department of Health and Human Services, pp. 205–49.
Randall T (1993). Morphine receptor cloned: improved analgesics, addiction therapy expected. JAMA, 270, 1165–6.
Rathod NH (1977). Follow-up study of injectors in a provincial town. Drug and Alcohol Dependence, 2, 1–21.
Rawson RA , Hasson AL , Huber AM , et al. (1998). A 3-year progress report on the implementation of LAAM in the United States. Addiction, 93, 533–40.
Reisine T & Pasternak G (1996). Opioid analgesics and antagonists. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn, ed. JG Hardman & LE Limbird . New York: McGraw-Hill, pp. 521–55.
Reisine T & Pasternak G (1996). Opioid analgesics and antagonists. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn, ed. JG Hardman & LE Limbird . New York: McGraw-Hill, pp. 521–55.
Rexed B , Edmondson K , Khan I & Samson RJ (1984). Guidelines for the Control of Narcotic and Psychotropic Substances in the Context of the International Treaties. Geneva: WHO.
Ricaurte GA , McCann UD , Szabo Z & Scheffel U (2000). Toxicodynamics and long-term toxicity of the recreational drug, 3.4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’). Toxicology Letters, 112–113, 143–6.
Richmond RL & Anderson P (1994). Research in general practice for smokers and excessive drinkers in Australia and the UK. Addiction, 89, 35–62.
Riley D (1987). Management of the pregnant drug addict. Bulletin of the Royal College of Psychiatrists, 11, 362–5.
Riordan CE & Kleber HD (1980). Rapid opiate detoxification with clonidine and naloxone. The Lancet, 1, 1079–80.
Robbins T , Cardinal R , DiCiano P , et al. (2007). Neuroscience of drugs and addiction. In Drugs and the Future; Brain Science, Addiction and Society, ed. D Nutt , TW Robbins , GV Stimson , M Ince & A Jackson . London: Elsevier, pp. 11#x2013;87.
Robertson EB , David SL & Rao SA (1997). Preventing Drug Use among Children and Adolescents: A Research-based Guide for Parents, Educators, and Community Leaders. Bethesda, MD: NIDA.
Robertson JR (1985). Drug users in contact with general practice. British Medical Journal, 290, 34–5.
Rochester JA & Kirchner JT (1999). Ecstasy (3,4-methylenedioxymethamphetamine): history, neurochemistry, and toxicology. Journal of American Board of Family Practice, 12, 137–42.
Room R & Paglia A (1998). Preventing Substance Use: Problems Among Youth: A Literature Review and Recommendations. Research document series 142. Toronto: Addiction Research Foundation.
Roozen HG , de Waart R , van der Windt DA , et al. (2006). A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. European Neuropsychopharmacology, 16, 311–23.
Roozen HG , de Waart R , van der Windt DAWM, et al. (2006). A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. European Neuropsychopharmacology, 16, 311–23.
Rose RJ , Dick DM , Viken RJ , Pulkkinen L & Kaprio J (2001). Drinking or abstaining at age 14? A genetic epidemiological study. Alcoholism: Clinical and Experimental Research, 25, 1594–604.
Rosen MI , McMahon TJ , Hameedi FA , et al. (1996). Effect of clonidine pre-treatment on naloxone-precipitated withdrawal. Journal of Pharmacology & Experimental Therapeutics, 276, 1128–35.
Rosenberg NL & Sharp CW (1992). Solvent toxicity: A neurological focus. In Inhalant Abuse: A Volatile Research Agenda. NIDA research monograph 129, ed. CW Sharp , F Beauvas & R Spence . Rockville, MD: Department of Health and Human Services, pp. 117–71.
Ross HE , Swinson, R , Larkin EJ & Doumani S (1994). Diagnosing comorbidity in substance abusers: computer assessment and clinical validation. Journal of Nervous and Mental Disorders, 182, 556–63.
Rotgers F (1996). Behavioral theory of substance abuse treatment: bringing science to bear on practice. In Treating Substance Abusers: Theory and Technique, ed. F Rotgers , D Keller & J Morgenstern . New York: Guilford Press, pp. 174–201.
Roth AD & Pilling S (2007). The Competencies Required to Deliver Effective Cognitive and Behavioural Therapy for People with Depression and Anxiety Disorders. London: Department of Health.
Rounsaville BJ , Tierney T , Crit-Cristoph K , Weissman MW & Kleber HD (1982). Predictors of outcome in treatment of opiate addicts: evidence for the multidimensional nature of addicts' problems. Comprehensive Psychiatry, 23, 462–78.
Royal College of Psychiatrists and Association of Police Surgeons (2006). Substance Misuse Detainees in Police Custody: Guidelines for Clinical Management, 3rd edn. Report of a Medical Working Group. Council report CR132. London: Royal College of Psychiatrists.
Royal College of Psychiatrists, and Association of Police Surgeons (2000). Substance Misuse Detainees in Police Custody: Guidelines for Clinical Management, 2nd edn. Report of a Medical Working Group. Council report CR81. London: Royal College of Psychiatrists.
Royal Colleges of Physicians, Psychiatrists & General Practitioners (1995). Alcohol and the Heart in Perspective. Sensible Limits Reaffirmed. Report of a Joint Working Group. London: Royal Colleges.
Ruiz P , Strain EC & Langrod JG (2007). The Substance Abuse Handbook. Philadelphia: Lippincott Williams and Wilkins.
Ruiz P , Strain EC & Langrod JG (2007). The Substance Abuse Handbook. Philadelphia: Lippincott, Williams and Wilkins.
Rush CR , Hayes CA & Higgins ST (1998). Behavioral pharmacology of sedatives, hypnotics, and anxiolytics. In Handbook of Substance Abuse. Neurobehavioural Pharmacology, ed. RE Tarter , RT Ammerman & PJ Ott . New York: Plenum, pp. 435–70.
Russell MAH (1987). Nicotine intake and its regulation by smokers. In Tobacco Smoking and Nicotine: a Neurobiological Approach, ed. WR Martin , GRV Loon , ET Iwamoto & L Davis . New York: Plenum Publishing Corporation, pp. 25–50.
Rydell CP , Caulkins JP & Everingham S (1996). Enforcement of treatment, modelling the relative efficacy of alternatives for controlling cocaine. Operations Research, 44, 687–95.
Sardesai SP , Shinde Namdo S , Pateil Shailesh B , Rayate Mukta N & Muley B (2007). Tobacco handling by pregnant bidi workers: As hazardous as smoking during pregnancy. The Journal of Obstetrics and Gynecology of India, 57, 335–8.
Satel SL , Southwick SM & Gawin FH (1991). Clinical features of cocaine-induced paranoia. American Journal of Psychiatry, 148, 495–8.
Saum CA & Inciardi JA (1997). Rohypnol misuse in United States. Substance Use and Misuse, 32, 723–31.
Saunders JP , Aasland OG , Amundsen A , et al. (1993). Alcohol Consumption and Related Problems among Primary Health Care Patients: WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption. Geneva: WHO.
Saxon AJ , Clasyn DA , Kivlahan DR & Roszell DK (1993). Outcome of contingency contracting for illicit drug use in a methadone maintenance program. Drug and Alcohol Dependence, 31, 205–14.
Schifano F (1996). Cocaine misuse and dependence. Current Opinion in Psychiatry, 9, 225–30.
Schifano F (2004). A bitter pill? Overview of ecstasy (MDMA; MDA) related fatalities. Psychopharmacology (Berlin), 173, 242–8.
Schifano F , Corkery J , Deluca P , Oyefeso A & Ghodse AH (2006). Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994–2003). Journal of Psychopharmacology, 20, 456–63.
Schifano F , Corkery J , Gilvarry E , et al. (2005). Buprenorphine mortality, seizures and prescription data in the UK (1980–2002). Human Psychopharmacology: Clinical and Experimental, 20, 343–8.
Schifano F , Corkery J , Gilvarry E , et al. (2005). Buprenorphine mortality, seizures and prescriptions. Human Psychopharmacology: Clinical and Experimental, 20, 343–8.
Schifano F , Corkery J , Oyefeso A , Tonia T & Ghodse AH (2008): Trapped in the ‘K-hole’; overview of deaths associated with ketamine misuse in the UK (1993–2006). Journal of Clinical Psychopharmacology, 28, 114–6.
Schroeder SA (2007). A Hidden Epidemic. The Washington Post, Sunday, November 18, 2007, pp. B07. www.washingtonpost.com/wp-dyn/content/article/2007/11/16/AR2007111601618.html.
Scientific Committee on Tobacco, and Health (STOTH) (2004). Secondhand Smoke: Review of Evidence since 1998. Update of Evidence of Health Effects of Secondhand Smoke. London: Department of Health.
Scottish Government (2008). The Road to Recovery: A New Approach to Tackling Scotland's Drug Problem. 29 May 2008. Edinburgh: The Scottish Government. www.scotland.gov.uk/Resource/Doc/224480/0060586.pdf.
Scottish Health Action on Alcohol Problems (2007). Alcohol: Price, Policy and Public Health. Edinburgh: SHAAP. www.shaap.org.uk/UserFiles/File/Price%20 Report%20-%20Full%20report.pdf.
Sellers EM (1984). Diazepam tapering in detoxification for high dose benzodiazepine abuse. Clinical Pharmacology and Therapeutics, 36, 410–16.
Sellers EM (1988). Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management. Canadian Medical Association Journal, 139, 113–18.
Selzer ML (1971). The Michigan alcoholism screening test: the quest for a new diagnostic instrument. American Journal of Psychiatry, 127, 1653–8.
Serper MR , Chou JC , Allen MH , Czobor P & Cancro R (1999). Symptomatic overlap of cocaine intoxication and acute schizophrenia at emergency presentation. Schizophrenic Bulletin, 25, 387–94.
Seymour RB & Smith DE (1998). Psychological and psychiatric consequences of hallucinogens. In Handbook of Substance Abuse. Neurobehavioural Pharmacology, ed. RE Tarter , RT Ammerman & PJ Ott . New York: Plenum. pp. 241–51.
Shedler J & Block J (1990). Adolescent drug use and psychological health: a longitudinal inquiry. American Psychologist, 45, 612–30.
Sherman MF & Bigelow GE (1992). Validity of patients' self-reported drug use as a function of treatment status. Drug and Alcohol Dependence, 30, 1–11.
Shiloh R , Nutt D & Weizman A (1999). Atlas of Psychiatric Pharmacotherapy. London: Martin Dunitz.
Shufman EN , Porat S , Witztum E , et al. (1994). The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biological Psychiatry, 35, 935–45.
Siegel E & Wasson S (1990). Sudden death caused by inhalation of butane and propane. New England Journal of Medicine, 323, 1638.
Silagy C , Lancaster T , Stead L , Mant D & Fowler G (2004). Nicotine replacement therapy for smoking cessation, Cochrane Database of Systematic Reviews (Online), 3, CD000146.
Silverman K , Higgins ST , Brooner RK , et al. (1996). Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Archives of General Psychiatry, 53, 409–15.
Simojoki K , Vorma H & Alho H (2008). A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (suboxone). Substance Abuse Treatment, Prevention and Policy, 3, 16.
Singh S (2007). Adolescent salvia substance abuse. Addiction, 102, 823–4.
Singleton N , Meltzer H , Gatward R , Coid J & Deasy D (1998). Psychiatric Morbidity among Prisoners in England and Wales. London: Office for National Statistics.
Singleton N , Pendry E , Taylor C , Farrell M & Marsden J (2003). Drug-Related Mortality among Newly Released Offenders. Report no. 187. London: Home Office Research, Development and Statistics Directorate. www.homeoffice.gov.uk/rds/pdfs2/r187.pdf.
Slattery J , Chick J , Cochraine M , et al. (2003). Prevention of Relapse in Alcohol Dependence. Health Technology Assessment Report 3. Glasgow: Health Technology Board for Scotland.
Sloboda Z , Baker O , Mounteney J & Neaman R (eds.) (1998). State of the Art of Prevention Research in the United States. Evaluating Drug Dependence in the European Union. Luxembourg: Office for Official Publications of the European Communities, pp. 31–44.
Smith C , Lizotte A , Thomberry T , et al. (1995). Resilient youth: identifying factors that prevent high-risk youth from engaging in serious delinquency and drug use. In Delinquency and Disrepute in the Life Course. Current Perspectives on Aging and the Life Cycle Series 4, ed. J Hagan . Greenwich, CT: JAI Press, pp. 217–47.
Smith K (2008). Seizures of Drugs in England and Wales, 2006/07. Home Office Statistical Bulletin 12/08. 30 October 2008. London: Home Office Research Development and Statistics Directorate. www.homeoffice.gov.uk/rds/pdfs08/hosb1208.pdf.
Soares BG , Lima MS , Reisser AA & Farrell M (2003). Dopamine agonists for cocaine dependence. Cochrane Database of Systematic Reviews (Online), 2, CD003352. PMID: 12804461.
Solowij N (1993). Ecstasy C3, 4-methylenedioxymethamphetamine. Current Opinion in Psychiatry, 6, 411–15.
Sondhi A , O'Shea J & Williams T (2002). Arrest Referral: Emerging Findings from the National Monitoring and Evaluation Programme. DPAS Paper 18. London: Home Office Drug Prevention Advisory Service. http://drugs.homeoffice.gov.uk/publication-search/Archive/DPAS_EM_Region_Business_Pl1.pdf?view=Binary.
Spear HB & Glatt MM (1971). The influence of Canadian addicts on heroin addiction in the United Kingdom. British Journal of Addiction, 66, 141–9.
Spear HB (1969). The growth of heroin addiction in the United Kingdom. British Journal of Addiction, 64, 245–56.
Stark K , Müller R , Bienzle U & Guggenmoos- Holzmann I (1996). Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin. AIDS, 10, 311–17.
Stimson G & Oppenheimer E (1982). Heroin Addiction: Treatment and Control in Britain. London: Tavistock, pp. 229–52.
Stimson GV (1995). AIDS and injecting drug use in the United Kingdom 1987–1993: the policy response and the prevention of the epidemic. Social Science Medicine, 5, 699–716.
Stitzer ML , Bigelow GE & McCaul ME (1985). Behaviour therapy in drug abuse treatment: review and evaluation. In Progress in the Development of Cost-Effective Treatment for Drug Abusers. NIDA research monograph series 58, ed. RS Ashery . Rockville, MD: Department of Health and Human Services.
Stitzer ML , Iguchi MY & Felch LJ (1992). Contingent take-home incentive: effects on drug use of methadone maintenance patients. Journal of Consulting and Clinical Psychology, 60, 927–34.
Stitzer ML , Iguchi MY , Kidorf M & Bigelow GE (1993). Contingency management in methadone treatment: the case for positive incentives. In Behavioral Treatments for Drug Abuse and Dependence. NIDA research monograph series 137, ed. LS Onken , JD Blaine & JJ Boren . Rockville, MD: NIDA, pp. 19–36.
Strang J , Bearn J & Gossop M (1997). Opiate detoxification under anaesthesia: enthusiasm must be tempered with caution and scientific scrutiny. British Medical Journal, 315, 1249–50.
Strassman RJ (1984). Adverse reactions to psychedelic drugs: a review of the literature. Journal of Nervous and Mental Disease, 171, 577–95.
Sudbury P & Ghodse AH (1991). Substance abuse and antisocial behaviour. Current Opinion in Psychiatry, 4, 440–7
Sudbury PR & Ghodse AH (1990). Solvent misuse. Current Opinion in Psychiatry, 3, 388–92.
Sutherland G , Stapleton J , Russell MAH , et al. (1992). Randomized controlled trial of nasal nicotine spray in smoking cessation. The Lancet, 340, 324–9.
Sweeting MJ , De Angelis D , Brant LJ , et al. (2007). The burden of hepatitis C in England. Journal of Viral Hepatitis, 14, 570–6.
Talhout R , Opperhuizen A & van Amsterdam JG (2007). Role of acetaldehyde in tobacco smoke addiction. European Neuropsychopharmacology, 17, 627–36.
Tanda G , Munzar P & Goldberg S (2000). Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nature Neuroscience, 3, 1073–4.
Taylor NS , Standen PJ , Cutajar P , Fox D & Wilson DN (2004). Smoking prevalence and knowledge of associated risks in adult attenders at day centres for people with learning disabilities, Journal of Intellectual Disability Research, 48, 239–44.
The Academy of Medical Sciences (2008). Brain Science, Addiction and Drugs: An Academy of Medical Sciences Working Group Report Chaired by Professor Sir Gabriel Horn FRS FRCP. London: Academy of Medical Sciences. ISBN: 1 903401 18 6.
The Academy of Medical Sciences (2008). Brain Science, Addiction and Drugs: An Academy of Medical Sciences Working Group Report Chaired by Professor Sir Gabriel Horn FRS FRCP. London: Academy of Medical Sciences. ISBN: 1 903401 18 6.
The British Pain Society (2007). Pain and Substance Misuse: Improving the Patient Experience. London: The British Pain Society. www.britishpainsociety.org.
The European Collaborative Study (1999). Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS, 13, 1377–85.
The European Monitoring Centre for Drugs, and Drug Addiction (date accessed: 1 July 2009). Drugnet Europe: News from the European Monitoring Centre for Drugs and Drug Addiction – October–December 2007. Lisbon: EMCDDA. www.emcdda.europa.eu/html.cfm/index 41242EN. html.
The Lancet (1857). What are the effects of smoking on the human frame? Editorial. The Lancet, 69, 270–1.
The Renal Association (date accessed: 24 June 2009). About eGFR. www.renal.org/pages/pages/other-info/ckd/about-egfr.php.
The United Kingdom Workplace Drug Testing Forum (2001). United Kingdom Laboratory Guidelines for Legally Defensible Workplace Drug Testing, Version 1.0. www.ltg.uk.net/admin/files/WPDT_guidelines.pdf.
Thomas HC (1996). Clinical features of viral hepatitis. In Oxford Textbook of Medicine, 3rd edn, ed. DJ Weatherall , JGG Ledingham & DA Warrell . Oxford: Oxford University Press, pp. 2061–9.
Thomson LDG (2000). Substance abuse and criminality. Current Opinion in Psychiatry, 12, 653–7.
Thorley A (1981). Longitudinal studies of drug dependence. In Drug Problems in Britain: A Review of Ten Years, ed. G Edwards & C Busch . London: Academic Press, pp. 117–69.
Timofeev MF (1999). Effects of acupuncture and an agonist of opiate receptors on heroin dependent patients. American Journal of Chinese Medicine, 27, 143–8.
Trinkoff AM & Storr CL (1998). Substance use among nurses: differences between specialties. American Journal of Public Health, 88, 581–5.
Tucker C (1990). Acute pain and substance abuse in surgical patients. The Journal of Neuroscience Nursing, 22, 339–50.
Turnbull PJ , McSweeney T , Webster R , Edmunds M & Hough M (2000). Drug Treatment and Testing Orders: Final Evaluation Report. Home Office Research Study 212. London: Home Office Research, Development and Statistics Directorate. www.homeoffice.gov.uk/rds/pdfs/hors212.pdf.
Tyrer P & Murphy S (1987). The place of benzodiazepines in psychiatric practice. British Journal of Psychiatry, 151, 719–23.
United Nations (1946). Protocol Amending the Agreements, Conventions and Protocols on Narcotic Drugs, 1946, Treaty series, vol. 12, p. 179.
United Nations (1946). Protocol Bringing under International Control Drugs Outside the Scope of the Convention of 13 July 1931 for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs as Amended by the Protocol, 1946, Treaty series, vol. 44, p. 277.
United Nations (1953). Protocol for Limiting and Regulating the Cultivation of the Poppy Plant, the Production of, International and Wholesale Trade in, and Use of Opium, 1953, Treaty series, vol. 456, p. 3.
United Nations (1961). Single Convention on Narcotic Drugs, 1961, Treaty series, vol. 520, no. 7515.
United Nations (1971). Convention on Psychotropic Substances, 1971, Treaty series, vol. 1019, no. 14956.
United Nations (1972). Protocol Amending the Single Convention on Narcotic Drugs, 1961, Treaty series, vol. 976, no. 14152.
United Nations (1990). Political Declaration and Global Programme of Action. (Feb A/Res/S-17/2.)
United Nations (1994). United Nations Conference for the Adoption of a Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, Vienna, 25 November – 20 December 1988: Official Records, vol. I. New York: United Nations Publications (sales no. E.94.XI.5).
United Nations (1994). United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988. United Nations Conference for the Adoption of a Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, Vienna, 25 November – 20 December 1988: Official Records, vol. 1. New York: United Nations Publications (sales no. E.94.XI.5).
United Nations General Assembly (1998). Declaration of the Guiding Principles of Drug Demand Reduction. (A/S-20/11.)
United Nations General Assembly (1999). Action Plan for the Implementation of the Declaration on the Guiding Principles of Drug Demand Reduction A/54/132, Annex.
United Nations International Drug Control Programme (1996). Amphetamine-Type Stimulants: A Global Review. Vienna: UNDCP.
United Nations International Drug Control Programme (1997). World Drug Report 1997. New York: Oxford University Press.
United Nations Office for Drug Control and Crime Prevention (1997). World Drug Report. New York: Oxford University Press.
United Nations Office for Drug Control, and Crime Prevention (2000). World Drug Report 2000. Geneva: United Nations Publications. www.unodc.org/pdf/world_drug_report_2000/report_2001–01–22_1.pdf.
United Nations Office on Drugs and Crime (2008). Annual Report 2008 Covering Activities in 2007. Vienna: United Nations Publications.
United Nations Office on Drugs and Crime (2008). World Drug Report 2008. United Nations Publications (ISBN: 978 92 1 148229 4).
United Nations Office on Drugs and Crime/World Health Organization (2008). Principles of Drug Dependence Treatment. Discussion Paper. Geneva: WHO.
United Nations Office on Drugs, and Crime (2008). 2008 World Drug Report. New York: United Nations Publications. www.unodc.org/documents/wdr/WDR_ 2008/WDR_2008_Eng_web.pdf.
United Nations Office on Drugs, and Crime (2008). Reducing the Adverse Health and Social Consequences of Drug Abuse: A Comprehensive Approach. New York: United Nations Publications.
US Centers for Disease Control, and Prevention (2005). Annual smoking-attributable mortality, years of potential life lost, and productivity losses – United States, 1997–2001. Morbidity and Mortality Weekly Report, 54, 625–8.
US Department of Health, and Human Services (1996). Treatment Works. Rockville, MD: DHHS.
US Surgeon General (2004). The 2004 Surgeon General's Report – The Health Consequences of Smoking. Washington, DC: Department of Health and Human Services. Available at: www.cdc.gov/tobacco/data_statistics/sgr/2004/complete_report/index.htm.
Van Dyke C & Byck R (1983). Cocaine use in man. In Advances in Substance Abuse, vol. 3, ed. NK Mello . Greenwich, CT: JAI Press, pp. 1–24.
Volkow ND , Wang GJ , Fowler JS , et al. (2004). Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. American Journal of Psychiatry, 161, 1173–80.
Wagner CC & Ingersoll JS (2008). Beyond cognition. Broadening the emotional base of motivational interviewing. Journal of Psychotherapy Integration, 18, 191–206.
Wall TL , Horn SM , Johnson ML , Smith TL & Carr LG (2000). Hangover symptoms in Asian Americans with variations in the aldehyde dehydrogenase gene. Journal of Studies on Alcohol, 61, 13–17.
Walsh SL , Johnson RE , Cone EJ & Bigelow GE (1998). Intravenous and oral l-alpha acetylmethadol: pharmacodynamics and pharmacokinetics in humans. Journal of Pharmacology and Experimental Therapeutics, 285, 71–82.
Walsh SL , Preston KL , Stitzer ML , Cone EJ & Bigelow GE (1994). Clinical pharmacology of buprenorphine: ceiling effect of high doses. Clinical Pharmacology and Therapeutics, 55, 569–80.
Watson CH , Polzin GM , Calafat AM & Ashley DL (2003). Determination of tar, nicotine, and carbon monoxide yields in the smoke of bidi cigarettes. Nicotine & Tobacco Research, 5, 747–53.
Wazaify M , Kennedy S , Hughes CM & McElnay JC (2005). Prevalence of over-the-counter drug-related overdoses at Accident and Emergency departments in Northern Ireland – a retrospective evaluation. Journal of Clinical Pharmacy and Therapeutics, 30, 39–44.
Weaver T , Madden P , Charles V , et al. (2003). Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. British Journal of Psychiatry, 183, 304–13.
Webb E , Ashton CH , Kelly PH & Kamali F (1996). Alcohol and drug use in UK university students. The Lancet, 348, 922–5.
Wells (1990). Psychosocial interventions. In Substance Abuse and Dependence, ed. AH Ghodse & D Maxwell . London: Macmillan Press, pp. 149–75.
Wells C (2009). Deaths related to drug poisoning in England and Wales, 2008. Health Statistics Quaterly, Autumn, 43, 48–55.
Welsh Assembly Government (2008). Working Together to Reduce Harm – The Substance Misuse Strategy for Wales 2008–2018. 1 October 2008. Cardiff: Welsh Assembly Government. http://wales.gov.uk/dsjlg/publications/commmunitysafety/strategy/strategye.pdf?lang=en.
Wen HI & Cheung SY (1973). Treatment of drug addiction by acupuncture and electrical stimulation. Asian Journal of Medicine, 9, 138–41.
Whelton A (1995). Renal effects of over-the-counter analgesics. Journal of Clinical Pharmacology, 35, 454–63.
Who Expert Committee on Drug Dependence (1988). Thirtieth Report. Technical report series 873. Geneva: WHO.
Wieder H & Kaplan EH (1969). Drug use in adolescents: psychodynamic meaning and pharmacogenic effect. Psychoanalytic Study of the Child, 24, 399–431.
Wilens TE & Biederman J (1992). The stimulants. Psychiatric Clinics of North America, 15, 191–222.
Williams H & Ghodse AH (1996). The prevention of alcohol and drug misuse. In The Prevention of Mental Illness in Primary Care, ed. A Kendrick , A Tylie & P Freeling . Cambridge: Cambridge University Press, pp. 223–45.
Williams H , Salter M & Ghodse AH (1996). Management of substance misusers on the general hospital ward. British Journal of Clinical Practice, 50, 94–8.
Williams P (1981). Trends in the prescribing of psychotropic drugs. In The Misuse of Psychotropic Drugs, ed. R Murray , H Ghodse , C Harris , D Williams & P Williams . London: Gaskell, Royal College of Psychiatrists.
Winters KC , Stinchfield RD , Opland E , Weller C & Latimer WW (2000). The effectiveness of the Minnesota Model approach in the treatment of adolescent drug abusers. Addiction, 95, 601–12.
Wood DM , Button J , Ashraf T , et al. (2008). What evidence is there that the UK should tackle the potential emerging threat of methamphetamine toxicity rather than established recreational drugs such as MDMA (‘ecstasy’)? QJM, 101, 207–13.
Woods JH , Katz JL & Winger G (1992). Benzodiazepines: use, abuse, and consequences. Pharmacological Reviews, 44, 151–347.
World Health Organization (1969). WHO Expert Committee on Drug Dependence. Sixteenth Report. Technical report series 407. Geneva: WHO.
World Health Organization (1983). The Use of Essential Drugs. Report of a WHO Expert Committee. Technical report series 685. Geneva: WHO.
World Health Organization (1988). Ethical Criteria for Medicinal Drug Promotion. Geneva: WHO.
World Health Organization (1989). WHO Expert Committee on Drug Dependence: Twenty Fifth Report. Technical report series 775. Geneva: WHO.
World Health Organization (1992). The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO.
World Health Organization (1992). The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO.
World Health Organization (1993). Health Promotion in the Work Place: Alcohol and Drug Abuse. Report of a WHO Expert Committee. Technical report series 833. Geneva: WHO.
World Health Organization (1993). Health Promotion in the Work Place: Alcohol and Drug Abuse. WHO expert committee. Technical report series 833. Geneva: WHO.
World Health Organization (1993). WHO Expert Committee on Drug Dependence. Twenty Eighth Report. Technical report series 836. Geneva: WHO.
World Health Organization (1993). WHO Expert Committee on Drug Dependence. Twenty Eighth Report. Technical report series 836. Geneva: WHO.
World Health Organization (1994). Lexicon of Alcohol and Drug Terms. Geneva: WHO.
World Health Organization (1994). Multi-City Study on Drug Injecting and Risk of HIV Infection. Geneva: WHO. http://whqlibdoc.who.int/hq/1994/WHO_PSA_ 94.4.pdf.
World Health Organization (1998). WHO Expert Committee on Drug Dependence. Thirtieth Report. Technical report series 873. Geneva: WHO.
World Health Organization (1998). Who Expert Committee on Drug Dependence. Thirtieth Report. Technical report series 873. Geneva: WHO.
World Health Organization (1999). Global Status Report on Alcohol. Geneva: WHO.
World Health Organization (2002). Quantifying selected major risks to health. In The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva: WHO, pp. 47–97. www.who.int/whr/2002/en/whr02_En.pdf.
World Health Organization (2004). Neuroscience of Psychoactive Substance Dependence. Geneva: WHO.
World Health Organization (2004). Neuroscience of Psychoactive Substance Use and Dependence. Geneva: WHO.
World Health Organization (2004). Neuroscience of Psychoactive Substance Use and Dependence. Geneva: WHO.
World Health Organization (2004). Neuroscience of Psychoactive Substance Use and Dependence. Geneva: WHO.
World Health Organization (2007). Gender and Tobacco Control: A Policy Brief. Geneva: Department of Gender, Women and Health, Tobacco Free Initiative, WHO.
World Health Organization (2007). Guidance on Regulations for the Transport of Infectious Substances 2007–2008. Geneva: WHO. www.who.int/csr/resources/publications/biosafety/WHO_CDS_EPR_2007_2cc.pdf.
World Health Organization (2008). WHO Report on the Global Tobacco Epidemic, 2008 – The MPOWER Package. Geneva: WHO.
Wright NM & Tompkins CN (2006). A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users. Harm Reduction Journal, 3, 27.
Wyatt SA & Ziedonis D (1998). Psychological and psychiatric consequences of amphetamines. In Handbook of Substance Abuse. Neurobehavioural Pharmacology, ed. RE Tarter , RT Ammerman & PJ Ott . New York: Plenum, pp. 529–44.
Yandoli D , Eisler I , Robbins C , et al. (2002). A comparative study of family therapy in the treatment of opiate users in a London drug clinic. Journal of Family Therapy, 24, 402–22.
Young RM , Lawford BR , Nutting A & Noble EP (2004). Advances in molecular genetics and the prevention and treatment of substance misuse: implications of association studies of the A1 allele of the D2 dopamine receptor gene. Addictive Behaviors, 29, 1275–94.
Zacune J (1971). A comparison of Canadian narcotic addicts in Great Britain and Canada. Bulletin on Narcotics, 23, 41.
Zador D (2001). Injectable opiate maintenance in the UK: is it good clinical practice? Addiction, 96, 547–53.
Zanis DA , Coviello D , Alteman AI & Appling SE (2001). A community based trial of vocational problem-solving to increase employment among methadone patients. Journal of Substance Abuse Treatment, 21, 19–26.
Zhang Z , Friedmann PD & Gerstein DR (2003). Does retention matter? Treatment duration and improvement in drug use. Addiction, 98, 673–84.
Zickler P (2004). Blood-borne Medications that Could Intercept Drugs before They Reach the Brain. NIDA Notes. Research on Cocaine. Washington: National Institute on Drug Abuse.
Ziedonis DM , Amass L , Steinberg M , et al. (2008). Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug and Alcohol Dependence, 99, 28–36. DOI: 10.1016/j.drugalcdep. 2008. 06.016.
Zuckerman B & Brown E (1993). Maternal substance abuse and infant development. In Handbook of Infant Mental Health, ed. R Tsang . New York: Guilford Press, pp. 143–58.
Zuckerman B , Frank D & Brown E (1995). Overview of the effects of abuse and drugs on pregnancy and offspring. In Medications Development for the Treatment of Pregnant Addicts and their Infants, ed. CN Chiang & LP Finnegan . NIDA research monograph 149. Rockville, MD: NIDA, pp. 16–38.